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Abstract
Microfluidic devices provide a powerful platform for the study of blood biology due to their control of flow
geometry, shear flow conditions, and blood biochemistry. This thesis describes a series of microfluidic
approaches to investigate a range of pathological flow conditions and their effects on thrombus formation. An
impingement-post microfluidic device was designed to shear platelet-free plasma at pathological rates to
aggregate von Willebrand factor (VWF) into insoluble fibers held in place by a micropost. VWF fibers were
non-amyloid and resistant to ADAMTS13 and tissue plasminogen activator. Factors XIIa and XIa were
captured in VWF fibers during aggregation, and could initiate fibrin formation on VWF. When whole blood
was perfused over VWF fibers, platelets rolled, bound, and activated in a shear-dependent manner on the fiber
surface. To study the structure of thrombi formed in regions of flow separation/reattachment in diseased
arteries, another microfluidic device was designed to perfuse blood creating a stagnation point on a
thrombotic surface. For clotting over collagen/tissue factor surfaces, platelet thrombi exhibited core-shell
architecture with a P-selectin-positive, fibrin-rich core and a P-selectin-negative outer shell. VWF was present
throughout the clot structure at both low and high shear rates, but platelet and VWF deposition was markedly
decreased when N-acetylcysteine was added. In contrast, inhibition of fibrin polymerization did not change
the overall structure of the thrombi, suggesting VWF is more important to clot stability at stagnation points.
N-acetylcysteine was found to reduce deposition of VWF on collagen, but was not able to dissolve VWF fibers
formed at pathological shear rates in the impingement-post device. Shear-induced platelet activation (SIPA)
on VWF was analyzed by stretching VWF with bound platelets using increasing shear rate to measure platelet
activation. As VWF fibers stretched in shear flow, the proportion of activated platelets (measured by P-selectin
exposure) also increased. Platelets bound to sorbed, non-stretchable VWF displayed the same activation
pattern, suggesting fluid shear is more important in SIPA than VWF stretching. GPVI-bound soluble fibrin
inhibits platelet activation by collagen. Developing new microfluidic models of thrombosis may lead to a
better understanding of the mechanisms involved and produce diagnostic tests for thrombotic diseases.
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ABSTRACT 
 
A MICROFLUIDIC APPROACH FOR INVESTIGATING THE ROLE OF BLOOD FLOW 
IN THROMBOSIS  
Bradley A. Herbig 
Scott L. Diamond 
Microfluidic devices provide a powerful platform for the study of blood biology due to their 
control of flow geometry, shear flow conditions, and blood biochemistry. This thesis 
describes a series of microfluidic approaches to investigate a range of pathological flow 
conditions and their effects on thrombus formation. An impingement-post microfluidic 
device was designed to shear platelet-free plasma at pathological rates to aggregate von 
Willebrand factor (VWF) into insoluble fibers held in place by a micropost. VWF fibers were 
non-amyloid and resistant to ADAMTS13 and tissue plasminogen activator. Factors XIIa 
and XIa were captured in VWF fibers during aggregation, and could initiate fibrin formation 
on VWF. When whole blood was perfused over VWF fibers, platelets rolled, bound, and 
activated in a shear-dependent manner on the fiber surface. To study the structure of 
thrombi formed in regions of flow separation/reattachment in diseased arteries, another 
microfluidic device was designed to perfuse blood creating a stagnation point on a 
thrombotic surface. For clotting over collagen/tissue factor surfaces, platelet thrombi 
exhibited core-shell architecture with a P-selectin-positive, fibrin-rich core and a P-
selectin-negative outer shell. VWF was present throughout the clot structure at both low 
and high shear rates, but platelet and VWF deposition was markedly decreased when N-
acetylcysteine was added. In contrast, inhibition of fibrin polymerization did not change 
the overall structure of the thrombi, suggesting VWF is more important to clot stability at 
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stagnation points. N-acetylcysteine was found to reduce deposition of VWF on collagen, 
but was not able to dissolve VWF fibers formed at pathological shear rates in the 
impingement-post device. Shear-induced platelet activation (SIPA) on VWF was analyzed 
by stretching VWF with bound platelets using increasing shear rate to measure platelet 
activation. As VWF fibers stretched in shear flow, the proportion of activated platelets 
(measured by P-selectin exposure) also increased. Platelets bound to sorbed, non-
stretchable VWF displayed the same activation pattern, suggesting fluid shear is more 
important in SIPA than VWF stretching. GPVI-bound soluble fibrin inhibits platelet 
activation by collagen. Developing new microfluidic models of thrombosis may lead to a 
better understanding of the mechanisms involved and produce diagnostic tests for 
thrombotic diseases. 
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CHAPTER 1: INTRODUCTION  
1.1 Hemostasis and Thrombosis 
Hemostasis is the process which causes bleeding to stop following damage to a 
blood vessel [1]. The hemostatic response is primarily made up of the actions of platelets 
and coagulation, which work in concert to reduce blood loss. When vessel injury exposes 
subendothelial collagen and releases endothelial von Willebrand factor (VWF), platelets 
bind and activate to trigger primary aggregation to the injury site [2]. The activated platelets 
then release autocrine activators such as adenosine diphosphate (ADP) and thromboxane 
(TXA2), which promote secondary aggregation, further slowing the loss of blood through 
the injury site [2]. Simultaneously, exposed tissue factor (TF) initiates plasma coagulation 
resulting in the generation of thrombin at the injury site, which further promotes platelet 
activation, aggregation, and polymerization of fibrin. These processes strengthen the 
hemostatic clot to halt blood loss. 
Thrombosis, by contrast, occurs within diseased vessels where excessive clotting 
and platelet buildup within the lumen of the vessel lead to obstructed blood flow and 
potentially full vessel blockage [1]. It occurs in numerous life threatening diseases, such 
as coronary artery disease [3], stroke [4], and venous thromboembolism [5]. Among the 
main causes of thrombosis is disturbed blood flow [6], where both stagnating blood flows 
and pathologically high blood flows can lead to the buildup of thrombi within a vessel. In 
addition to the actions of platelets and coagulation described above, VWF circulating in 
the plasma can exacerbate the formation of clots in these disturbed flows by aggregating 
under high shear and extensional flow conditions and recruiting additional platelets [7]. 
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1.2 Platelets 
Platelets are anucleate disc-shaped cells (2-3 µm in diameter when quiescent [8]) 
that are the primary drivers of hemostasis and thrombosis. When exposed to platelet 
agonists, such as collagen or thrombin, platelets become activated through agonist-
specific surface receptors. Activation manifests itself in two stages. First, there is an 
increase in intracellular calcium, which causes the platelet cytoskeleton to spread and 
create filopodial protrusions from its surface via myosin II and actin filament interactions 
[9]. Second, activated platelets release a large number of species into the local 
environment, such as ADP, TXA2, and alpha granules. Alpha granules contain a number 
of clotting proteins, growth factors, and VWF, and express the adhesion molecule P-
selectin on the surface of degranulated platelets [10]. Because of this, P-selectin is a 
useful marker of platelet activation. 
1.3 Plasma Coagulation  
Plasma coagulation can be initiated by two distinct pathways: the contact (intrinsic) 
pathway and the tissue factor (extrinsic) pathway (Figure 1-1), both of which converge 
onto the common pathway to produce thrombin.  
The contact (intrinsic) pathway is initiated by plasma contact with anionic surfaces 
that activate factor XII to XIIa. After this initiating step, the cascade of activation continues 
by XIIa activating factor XI to XIa, leading up to the activation of factor IX to IXa and the 
formation of the intrinsic tenase, IXa/VIIIa. Following this reaction cascade, the intrinsic 
tenase then activates factor X to Xa, beginning the common pathway. The intrinsic 
pathway was thought to not be important in vivo because deficiencies in factors XII and XI 
are not associated with abnormal hemostasis or bleeding [11], but recent evidence 
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suggests that it is important in thrombosis. This suggests factors XII and XI could be ideal 
targets for anti-thrombotic drugs with low bleeding risk [12–14]. 
In the tissue factor (extrinsic) pathway, a disrupted endothelium, potentially from 
trauma, plaque rupture, or other vascular injury, exposes tissue factor (TF) to the blood. 
Circulating factor VII binds to TF in its activated form to form TF/VIIa, the extrinsic tenase, 
which like the intrinsic tenase begins the common pathway by activating factor X to Xa. 
Following the intrinsic and/or extrinsic pathways, the common pathway is initiated 
by factor Xa, which along with factor Va in the prothombinase complex catalyzes the 
activation of prothrombin to thrombin. Calcium ions play an essential role in assisting 
coagulation, because both intrinsic tenase and prothrombinase complexes require 
calcium ions and phospholipid surfaces to function [15]. 
Thrombin is the central protease in the coagulation cascade, and plays multiple 
roles both in coagulation, fibrin formation, and platelet activation [15]. In the coagulation 
cascade, thrombin is able to activate factor XI, causing a feedback loop which can self-
amplify thrombin production [16]. Thrombin also is able to cleave fibrinogen to form fibrin 
monomers, which then can be cleaved again by thrombin to polymerize into fibrin 
polymers, which are either soluble or insoluble depending on chain length. Thrombin also 
plays a significant role in platelet activation by cleaving PAR1 and PAR4 receptors on the 
platelet surface [15].  
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Figure 1-1: Simplified model of the coagulation cascade 
Blood coagulation can be initiated by two distinct pathways: the contact (intrinsic) pathway 
and the tissue factor (extrinsic) pathway. Both pathways merge to the common pathway, 
where factor Xa catalyzes the conversion of prothrombin to thrombin, which amplifies 
coagulation, polymerizes fibrin, and activates platelets. 
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1.4 Von Willebrand Factor 
1.4.1 Von Willebrand factor structure and multimer assembly 
Von Willebrand factor (VWF) is a blood glycoprotein involved in both hemostasis 
and thrombosis. VWF circulates in plasma in multimers that are variable in size. Each 
VWF monomer contains 2050 amino acids, and consists of a number of domains with 
specific binding sites and functions (Figure 1-2A). The D’/D3 domain binds factor VIII and 
heparin in circulation, as well as participating in VWF multimerization. The A1 domain 
binds to platelet GPIb, heparin, and collagen. The A2 domain, when partially unfolded by 
shear flow, exposes the cleavage site for ADAMTS13. The A3 domain contains the 
primary binding site collagen. The C1 domain contains the RGD motif enabling stable 
binding to platelets via GPIIb/IIIa. The CK “cysteine knot” participates in VWF dimerization, 
as well as binding to a number of growth factors. 
VWF monomers form multimers in a multi-step process before secretion [17] 
(Figure 1-2B). First, VWF monomers are N-glycosylated and form dimers at the CK 
domain in the acidic pH of the endoplasmic reticulum. The VWF dimers are then joined by 
disulfide bonds at the D’D3 domain in the Golgi apparatus to further multimerize. The VWF 
multimers are assembled into a helical shape in the trans-Golgi network and Weibel 
Palade bodies, which are unfurled when finally released into circulation by the endothelial 
cell. 
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Figure 1-2: VWF domain structure and multimerization 
(A) Domain structure of VWF and common binding locations that are involved in 
hemostasis and thrombosis. (B) VWF monomers assemble into multimers via 
dimerization, followed by multimerization before secretion by endothelial cells. They can 
then laterally aggregate into fibers via disulfide bonds along their length in high shear flow 
conditions. 
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1.4.2 Role of VWF in hemostasis and thrombosis 
Although VWF is present in the α-granules of platelets, it is primarily released from 
Weibel-Palade bodies in the endothelium as ultra-large VWF (ULVWF), described above. 
To enter the plasma, the tethered ULVWF has to be released from endothelial cells (Figure 
1-3). In hemostasis, these ULVWF strands that are tethered to activated endothelial cells 
around an injury help attract platelets to the site of injury. ULVWF tethers under strain from 
the shear flow of blood (potentially opening up the A2 domain) are then cleaved by a 
metalloprotease called ADAMTS13. Once cleaved and processed by ADAMTS13, an 
array of smaller VWF multimers circulate with molecular weight of ~1-~20 MDa in the 
plasma. Plasma VWF also can participate in hemostasis by binding exposed collagen 
under elevated shear flow, facilitating the binding of platelets to that collagen surface.  
VWF also can play a significant role in thrombosis. Whenever VWF multimers in 
plasma are exposed to high shear rates, such as while passing through a vessel stenosis 
or over a partially occlusive thrombus, the extensional flow stretches out the VWF 
multimers and exposes more hydrophobic domains along the protein [18], which cases 
VWF to aggregate into fibers that are resistant to ADAMTS13 [19]. These fibers can bind 
to the platelets on the top of the thrombus, which then allows them to recruit more platelets 
to the thrombus surface. Because of the high shear rates seen when vessels reach ~75% 
occlusion [20], VWF can drive nearly occlusive thrombi to occlusion [7]. Such extreme 
shear flows may also be relevant to VWF assembly during hemorrhagic bleeding of 
severed vessels. 
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1.4.3 Diseases involving VWF biology 
There are a number of genetic and acquired diseases surrounding VWF biology 
with different clinical manifestations. Defects in VWF number and/or function can lead to 
von Willebrand disease (VWD), which manifests in bleeding tendencies depending on the 
qualitative and quantitative severity of the disease [21]. Type 1 VWF (making up 60-80% 
of all cases) is a quantitative defect where VWF levels are detected at 20-50% of normal. 
These patients are mostly asymptomatic, but occasionally exhibit bleeding following 
surgery. Type 2 VWD (15-30% of cases) is a qualitative defect with four subtypes (A, B, 
M, N) with varying bleeding tendencies. Type 2A VWD is quantitatively normal, but 
qualitatively defective, resulting in only small multimers in circulations. Type 2B VWD is a 
gain of function defect, where VWF binding to GPIb is enhanced, leading to spontaneous 
platelet binding and clearance of both bound platelets and large VWF multimers, often 
resulting in thrombocytopenia. Type 2M VWD is a qualitative defect that reduces the ability 
of VWF to bind to GPIb, but does not affect multimerization. Type 2N VWD is a qualitative 
defect in the binding of VWF to FVIII, which is often misdiagnosed as hemophilia A 
because of VWF’s normal role of increasing FVIII half-life. Type 3 VWD is the most severe 
form of VWD where no VWF is produced. These patients see severe life-threatening 
bleeds similar to hemophilia A patients, highlighting the importance of VWF in hemostasis. 
Acquired VWD can occur in patients with aortic valve stenosis [22] or high shear 
medical devices such as left ventricular assist devices (LVADs) [23,24]. Acquired VWD 
takes on the pathology of Type 2A, with an absence of large VWF multimers in circulation. 
In patients with aortic valve stenosis, the high shear flow conditions at the stenosis led to 
a significant reduction of >15mer VWF in plasma, and spontaneous bleeding occurred in 
20% of patients as a result [22]. Replacement of stenosed aortic valves may be able to 
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reverse the effects of acquired VWD [22,25]. In LVADs, large multimers of VWF are 
destroyed by mechanical stress and cleared, leading to a severe quantitative defect. 
Multiple studies have shown that all patients with implanted LVADs have reduced high 
molecular weight VWF multimers, and a majority of those patients had bleeding 
complications [23,24]. Bleeding in LVAD patients is often GI bleeding and occurs many 
months after onset of the acquired VWD, suggesting additional vascular pathological 
mechanisms. 
When there is a defect in ADAMTS13 function (thrombotic thrombocytopenic 
purpura, TTP), circulating VWF multimers are much larger and form many micro-thrombi 
in circulation. The resulting platelet-rich thrombi then have downstream effects, like 
fragmenting red blood cells, causing thrombocytopenia, and causing ischemic damage to 
organs [26]. TTP is an acute medical emergency with high fatality rates if not properly 
diagnosed [27]. 
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Figure 1-3: VWF phenomena in low and high shear 
VWF participates in both physiological and pathological processes based on exposure to 
shear flow. At low shear rates (100-1500 s-1), ultra-large VWF (ULVWF) is released from 
activated endothelial cells (1) and extend into the vessel lumen. After being stretched out 
by shear flow, ADAMTS13 cleaves ULVWF into smaller multimers (2) that are released 
into circulation (3). These multimers are useful in hemostasis, but when exposed to high 
shear (>5000 s-1) pathologies such as vessel stenosis, severe thrombosis, or in high shear 
medical devices (e.g. LVADs), circulating VWF multimers are stretched out, aggregate 
into fibers, and can bind platelets to form thrombi (4).  
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1.5 Hemodynamics and Adhesion Mechanics 
Because platelets need to adhere to an injury site while they are flowing past in 
the bloodstream, the receptors and ligands involved in adhesion and arrest at the injury 
site need to be fast and strong enough to overcome the local fluid forces. In humans, blood 
flows at different velocities (and resulting wall shear rates) depending on the anatomical 
location, from 50-60 s-1 in the vena cava to 1000-5000 s-1 in some arterioles [28,29]. As a 
result, different platelet receptors and protein ligands are responsible for stable adhesion 
in different flow regimes. At shear rates below 500-800 s-1, platelets firmly bind to 
subendothelial exposed collagen via α2β1 and glycoprotein VI (GPVI) [30,31]. Above 500-
800 s-1, however, the only receptor-ligand reaction with a high enough on-rate is VWF and 
glycoprotein Ib (GPIb), which forms a “catch-slip” bond that manifests in platelet rolling 
along VWF fibers [30,31]. In order to stably bind at high shear rates, platelet glycoprotein 
IIb/IIIa (GPIIb/IIIa, also known as αIIbβ3) needs to activate via inside-out signaling and bind 
to VWF. This interaction can only occur once the platelet has been slowed enough by 
GPIb binding to increase its residence time on the VWF [32]. GPIIb/IIIa can also bind to 
deposited fibrinogen and fibrin at the site of subendothelial exposure, which facilitates the 
aggregation of platelets and leads to the formation of the hemostatic plug [33]. 
1.6 Microfluidics 
One particularly useful platform for studying the extreme blood flows is 
microfluidics. The vast array of microfluidic devices that have been developed and utilized 
have been useful in many fields, but microfluidic devices are particularly useful for studying 
extreme blood flows for their operational flexibility, control of fluid shear, and control of 
flow geometry. 
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1.6.1 Operational flexibility 
Microfluidics have been utilized extensively to design robust experiments to better 
understand biological mechanisms under conditions of fluid flow. This platform technology 
is particularly useful operationally because of its ease of use, versatility, scale, and control 
of fluid conditions. 
1.6.1.1 Ease of design and fabrication 
The design and manufacturing of microfluidic devices is well-developed and 
extensively described. The overall process is straightforward and allows for customization 
of device features and design iteration at relatively low costs. 
Device features are designed in computer-aided design (CAD) programs (e.g. 
DraftSight or AutoCAD), which are then made into photomasks at a printing company (e.g. 
OutputCity). Using these custom photomasks, the device features are transferred onto 
silicon wafers using standard photolithography[34]. The resulting silicon wafers can then 
be used as a reusable master mold to create polydimethylsiloxane (PDMS) microfluidic 
devices. These devices are made by degassing PDMS prepolymer and curing reagents, 
and curing them over the master wafer at 65°C for 3 hours. The temperature and time 
used depends on the design of the microfluidic devices, as high temperatures tend to 
shrink some features. Lower curing temperatures (45°C) and longer curing times (24 
hours) followed by curing at higher temperatures can be used for devices with more exact 
features[35]. After cooling, the molded PDMS can then be peeled off, cut into individual 
devices (if the initial design includes multiple devices per mask), and modified with 
appropriate hole-punches to create the inlets, outlets, and other ports in the final device. 
Because microfluidic devices used to study pathological flows often contain complex 
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geometries, the ease of fabrication enables an iterative approach to device design and 
experimental design. 
1.6.1.2 Ease of detection 
Another operational advantage of using microfluidic devices to study thrombosis 
in pathological flows is the ease with which spatiotemporal changes in clot structure and 
composition can be observed using a fluorescent microscope. Common fluorophores such 
as phycoerythrin (PE), allophycocyanin (APC), and fluorescein isothiocyanate (FITC) can 
be conjugated with antibodies against blood components like CD61 (platelets), CD62P (P-
selectin), fibrin, or VWF to fluorescently track thrombosis in microfluidic devices using 
different colors. This enables tracking of blood components and their relative 
concentrations in thrombi by measuring relative intensity of the fluorescent signal 
throughout the clot and over time. 
1.6.1.3 Scale and blood volumes  
One advantage that makes microfluidics particularly suited for use in studying 
extreme blood flows is the relatively small volumes of fluid necessary to run each 
experiment. Because the length scale of the channels on a microfluidic device are on the 
micrometer scale, even high shear experiments can be run at relatively low flow rates on 
the order of μL/min. Previous experimental technologies, such as parallel flow chambers, 
required multiple liters of blood to run an experiment with the same time length and shear 
rates that a couple milliliters could achieve in a microfluidic device. This scale advantage 
also enables potential diagnostic applications where blood volumes are limited (i.e. 
neonatal studies). 
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1.6.1.4 Control of blood biochemistry 
Microfluidics allow for significant control over blood biochemistry through the 
addition of a variety of anticoagulants, inhibitors, and drugs. In contrast to in vivo studies, 
where concentrations in blood are complicated by numerous factors, in vitro microfluidics 
enable precise control of exogenous species concentration in the blood, providing insights 
into the mechanisms involved. Blood begins the process of coagulation as soon as it is 
exposed to a negatively-charged surface, so anticoagulation is particularly important in 
microfluidic experiments. Numerous inhibitors of factors in the coagulation pathway are 
used, as well as calcium chelators.  
Direct inhibition of coagulation factors is a powerful tool in microfluidic studies of 
pathological flows. PPACK, a direct and potent inhibitor of thrombin, is used to study the 
role of platelets in thrombosis without the influence of coagulation. Apixaban is a Factor 
Xa inhibitor which can be used to prevent the endogenous production of thrombin without 
inhibiting any thrombin added to the experiment exogenously. Corn trypsin inhibitor (CTI) 
blocks Factor XIIa, and can be used at various concentrations for different effects. At a 
low concentration (~4 μg/mL), CTI prevents the contact activation from handling of blood 
during the experiment, but allows the formation of thrombin over a thrombotic surface, 
such as collagen. At a high concentration (~40 μg/mL), CTI is able to fully block the 
intrinsic coagulation pathway, allowing the study of the extrinsic pathway 
Calcium chelators, such as sodium citrate and ethylenediaminetetraacetic acid 
(EDTA), prevent the calcium-dependent coagulation pathway from initiating. By adding 
calcium ions back into the blood before or after introduction to the microfluidic device [36], 
coagulation can be reinitiated and clotting can proceed. Note that EDTA should only be 
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used in platelet-free experiments, because it has been shown to cause platelets to 
dissociate their αIIbβ3 integrins [37].  
Another manifestation of this advantage is in drug testing, where novel 
anticoagulants, anti-platelet agents, and other drug candidates can be examined for their 
effect on clot formation and dose-response relationship can be established. Because 
overall blood volumes are low, smaller amounts of these additions are necessary to test 
their effect on platelets and/or coagulation at sufficient concentrations. 
1.6.2 Control of fluid shear 
Microfluidics allow for precise control of fluid flow and shear conditions. Because 
the mechanisms that dominate clotting differ between flow regimes and patterns, this 
ability enables microfluidics to be a powerful platform in studying how pathological flows 
affect clot formation. Stenosis devices in particular have been useful in studying the role 
of VWF in high shear thrombosis. 
Colace et al. used a stenotic-shaped microfluidic device (Figure 1-4A) that sheared 
PFP or whole blood at pathological shear rates (> 30,000 s-1) and shear gradients over a 
patch of collagen to study the interactions between sheared VWF, platelets, and collagen 
[38]. Unlike typical viscometry experiments, these devices allowed for single-pass 
perfusion of PFP or whole blood over the collagen, which allowed them to study how short 
exposure to shear affects thrombotic potential. 
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Figure 1-4: VWF deposition on collagen and platelets occurs in stenosis 
microfluidic device 
A) COMSOL simulation demonstrates severe pathological wall shear rate in the stenosis 
device. B) EDTA-anticoagulated platelet-free plasma (PFP) was perfused over collagen 
at 125,000 s-1, resulting the deposition of VWF fibers. C) VWF fiber deposition on collagen 
was also observed in straight (non-stenotic) channels, suggesting shear gradients aren’t 
required for VWF aggregation at extremely high shear rates. D) A steady-state platelet 
clot on collagen was formed by flowing PPACK-anticoagulated whole blood at 200 s-1 for 
1500 seconds, followed by perfusion of PPACK-anticoagulated PFP at 23,400 s-1. VWF 
deposited in fibers on the platelet clot surface after 50 seconds. E) A schematic diagram 
of VWF deposition in the D [38].   
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Aggregation of VWF into fibers is driven by the high shear forces on plasma 
upstream, which causes tumbling in flow and stretches out VWF fibers to expose 
hydrophobic domains, which leads to lateral aggregation of VWF into fibers able to bind 
to the collagen surface (Figure 1-4B). These fibers were also observed to be fully bound 
to the collagen and did not relax when flow was stopped. Interestingly, the formation of 
VWF fibers on collagen did not require a shear gradient (Figure 1-4C), which contrasts 
with previous reports by Nesbitt et al [39]. It is possible that at lower shear rates, shear 
gradients are more important to VWF elongation and aggregation, but Colace and 
colleagues found that at extreme pathological shear rates, the high shear rate was 
sufficient to induce VWF fiber formation on collagen. High wall shear rate may be the 
dominant factor for VWF fiber bundle formation on a wall, whereas high shear rate gradient 
or elongation rate may be the critical factor for VWF bundle formation in bulk flow. 
When whole blood was perfused at pathological shear rates through the device, 
VWF/platelet nets formed, rolled, and embolized across the collagen surface, an effect 
blocked by anti-GPIb or the anti-αIIbβ3 inhibitor GR144053. When thrombi were allowed to 
grow to steady state on a collagen surface at low shear, followed by high shear perfusion 
of WB, VWF fibers formed on the surface of the clots through platelet GPIb (Figure 1-4D-
E). As a result, platelet recruitment was reestablished by increasing the GPIb/VWF 
tethering via increased VWF aggregation at high shear on the thrombus surface. The 
simple but extremely narrow stenotic channel shape over a collagen surface allowed for 
the capitulation of these severely pathological environments without requiring large 
volumes of blood. 
Another common type of stenosis-shaped microfluidic device relies on a short 
semi-circular region blocking 20-80% of the channel diameter to create high shear 
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conditions and observe the resulting clot formation. Westein and colleagues [40] patterned 
collagen in a striped pattern to compare the deposition of platelets and VWF at points 
upstream, within, and downstream of the stenosis region. In this device, platelet 
aggregation was enhanced in the stenotic outlet regions at 60-80% occlusion over a range 
of inlet wall shear rates. Nesbitt and colleagues [39] used a fully-collagen-coated stenosis 
microfluidic device to study the localization of platelets in low-shear zones at the 
downstream face of forming thrombi. They found that soluble agonists were not required 
for this aggregation in response to shear microgradients, which reinforces the crucial role 
that VWF plays in thrombus formation following high shear stenoses. 
Li and colleagues[41] also utilized a stenotic microfluidic device with a couple key 
differences in device scale and thrombotic surface placement. The stenotic channel was 
much larger than in the previously discussed stenosis devices, with a 750 μm channel 
tapering to 250 μm. This matches more closely with pathologically relevant eccentric 
constriction or stenosis, but requires the use of large volumes of blood, which reduces 
applicability to point-of-care diagnostic devices. Second, the full channel of the device was 
coated with collagen instead of localizing the thrombotic surface to patterned strips on the 
glass surface. However, they did not observe any platelet clotting upstream or 
downstream of the stenosis region, enabling it to be used for a highly systematic and 
systemic analysis of the effect of aspirin (ASA) and eptifibatide (GPIIb/IIIa inhibitor) on 
occlusive thrombosis and thrombus stability across a range of high shear rates.  
In this study, it was found that shear rates have significant effects on both occlusion 
time/dose-response curves for both therapies. For example, ASA had very little effect on 
high shear occlusion times, while eptifibatide was able to reduce occlusion and increased 
efficacy with dose at all shear rates tested. It was also found that high shear thrombi 
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formed in the presence of ASA were 4 times more likely to detach than either untreated 
or eptifibatide-treated controls. This and similar microfluidic devices that evaluate the 
efficacy of antiplatelet therapies under a wide range of shear rates are valuable to 
optimizing treatment models for high shear thrombotic diseases. 
1.6.3 Control of flow geometry 
Pathological flows occur in regions of the body with 3-dimensional geometry, 
including at stenoses, bifurcations, and within thrombi. Microfluidics can recapitulate these 
geometries to better understand clotting in pathological flows. Biomimetic stenoses, 
stagnation point geometries, and pathologic interstitial flow all have been studied using 
microfluidics. 
One common criticism of traditions square microfluidic channels is that they do not 
fully replicate the flow patterns found in round blood vessels. To address this, some groups 
have used a cylindrical piece of material that PDMS can cure around, and which can then 
be removed to leave behind a cylindrical-shaped microchannel. Mannino and 
colleagues[42] used a 500 μm diameter optical fiber as their cylindrical mold, which they 
modified to create the flow geometry of interest. To create a stenosis, a razor blade 
covered with fine sandpaper was used to sand a fine notch out of the optical fiber, resulting 
in the creation of a stenosis in the final PDMS device. Costa and colleagues[43] utilized 
3D-printing to recapitulate the 3D vessel geometry and local blood flow patterns in a 
microfluidic device. Although these devices do not fully recapitulate the 3D flow found in 
larger blood vessels due to the low Reynolds number nature of microfluidics, the round 
channels provide flow conditions more similar to the blood vessels than square channels 
can. 
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Using computed tomography angiography data of a coronary artery, both healthy 
and stenosis models of the vessel were 3D printed and used as a template for PDMS-
based soft lithography. The resulting channels were seeded with human umbilical vein 
endothelial cells to form a confluent monolayer. When recalcified citrated WB was 
perfused through the channels at an upstream wall shear rate of 1000 s-1, the healthy 
geometry did not show any sign of thrombosis along the length of the channel for 15 
minutes. The stenotic geometries (55% and 67% occlusion) both displayed thrombosis in 
the downstream portion of the stenosis beginning at 2 minutes, with significant platelet 
aggregation in the recirculation zone. Because shear rates in the stenosis reached 
>10,000 s-1, VWF also likely played a role in recruiting platelets to the thrombus. The 
innovative combination of 3D printing and traditional PDMS-based soft lithography 
demonstrated how 3D hemodynamics can studied using microfluidic techniques. 
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CHAPTER 2:  MICROFLUIDIC DEVICE DESIGN 
2.1 Microfluidic Design Process 
2.1.1 Problem definition and brainstorming 
Microfluidics is a powerful platform for studying a variety of topics, particularly 
where fluid flow is involved. The process of designing a microfluidic device, either for a 
single experiment or as a versatile multi-project device, begins with identifying which 
capabilities are necessary for success. To mimic a piece of vasculature, what kind of shear 
rates and geometry are needed? How will any resulting data be measured? The ease with 
which microfluidic designs can be iterated allows some leeway for more specific questions, 
but it helps to have a defined hypothesis to guide the design of the device. 
Before starting to draw designs on the computer, begin by brainstorming ideas on 
paper. The advantages of this are two-fold: drawing designs on paper is faster and allows 
for easy recall, compilation, and modification of ideas. Drawing also enables spatial 
awareness of where different features will be relative to each other and how they should 
be arranged on the device. How will the device connect to any auxiliary pumps, actuators, 
or pressure sensors?  
2.1.2 Simulation and design 
After arriving at one or more designs that enable proof-of-concept experiments, 
draw the designs using a computer aided drafting (CAD) program, such as Solidworks or 
Draft Sight, keeping in mind the scale of the CAD drawing. Begin by drawing the fluid 
contacting channels, taking care that all of the lines surrounding a channel connect. In the 
first iteration of the drawing (which will be used in simulations), do not draw any of the inlet 
or outlet ports, or non-fluid-contacting features. A series of interconnected channels with 
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lines capping the inlets and outlets is ideal for testing in computational flow dynamics 
simulators, such as COMSOL. Save this file as a *.dxf for import into COMSOL. 
In COMSOL, insert a work plane into a laminar flow simulation file and import the 
microfluidic design onto the work plane. Extrude the plane to the desired channel height 
within the limits of the photolithography to create a 3D structure of the channels. Adjust 
the viscosity and density of the simulated fluid to match the desired fluid (e.g. blood or 
platelet-free plasma). Select the flow path, and specify the inlets and outlets and their 
respective flow rates or pressures (including those open to the atmosphere). Run the 
simulation, and examine the velocity and pressure results to determine if the design 
worked as intended. Other important characteristics of the flow, such as wall shear rate, 
can be displayed through the results menus. If the design meets the intended 
specifications, finalize the CAD drawing for the photomask to include inlet and outlet ports, 
a seal surrounding the channels, and posts to enable vacuum sealing to glass slides. 
Multiple device designs or duplicate designs can be included in the design to produce 
multiple devices per wafer at a time. 
2.1.3 Device testing and iteration 
To translate the design into a physical device, first send the CAD drawing to a 
photomask printing company (e.g. OutputCity), and specify that the microfluidic channels 
should be clear on the mask and emulsion side should be down as viewed on the screen 
(to improve photolithographic resolution). Once the mask is received (Figure 2-1A), 
previously described soft lithographic techniques [44] can be used to fabricate a mold for 
the microfluidic devices by preferentially patterning a negative photoresist (KMPR 1050, 
MicroChem Corp.) on a silicon waver (D = 100 mm, WRS Materials). Spin the photoresist 
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on the wafer to a height of 60 µm using a spin coater and soft bake it for 20 minutes. After 
baking, place the substrate beneath the photomask and expose it to UV illumination to 
crosslink the mask pattern onto the wafer. Bake it for an additional 4 minutes at 100°C, 
and develop the photoresist using AZ® 300 MIF (AZ Electronic Materials USA Corp.) until 
the mask pattern is visible on the wafer. Tape the wafer into a large petri dish container, 
which will be used as the mold for the device (Figure 2-1B). Pour PDMS, with a base to 
curing agent ratio of 10:1, over the mold, ensuring minimal introduction of air into the 
polymer, and cure the PDMS for 2 hours at 80°C. Peel the now solid PDMS puck off of 
the mold, and cut the devices to size. Inlet/outlet, vacuum, and other ports can be cut out 
using core-punchers (Harris Uni-Core™), and multiple PDMS layers can be bonded 
together using a plasma treatment to create the final devices (Figure 2-1C).  
With completed microfluidic devices in hand, run the proof of concept experiments 
determined during the design stage. With these results, decide which features work best, 
which elements to omit, and iterate the design. Once a final, fully-functional design is 
found, it is often helpful to create a wafer that includes multiple copies of that best design 
to aid in experimental replication. Be sure to note any potential alterations that could be 
made to the device after this stage, as they may lead to new designs that will enable future 
studies.  
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Figure 2-1: Microfluidic device production 
(A) After finalizing the CAD drawing for the device, a photomask was printed using a 
commercial service. (B) Using well documented techniques for photolithography, a wafer 
with the microfluidic design was produced for use as a mold. (C) Final microfluidic device 
is produced by pouring PDMS over the mold and baking to harden. Holes for inlets, outlets, 
and vacuum lines were punched through the device, and the device was sealed to a glass 
slide via a vacuum pump.  
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2.2 Common Microfluidic Features 
There are a number of common features used in microfluidic device design that 
are useful for controlling the fluid path, adding a thrombotic surface, and making the device 
more reusable. Stenosis-shaped channels (Figure 2-2A) are those which narrow in width 
for a certain length of channel before expanding again to the full inlet width. This type of 
channel is useful for increasing the shear rate in the narrowed part of the channel, with 
the advantage of using less fluid volume to achieve a higher shear rate than a straight 
channel would. When a microfluidic device runs in multiple stages (e.g. collagen is loaded 
into the device before blood is introduced to clot on it), plugging inlets and outlets (Figure 
2-2B) enables redirection of the fluid path to prevent the mixture of reagents before the 
time of the experiment, or use of different channels at different times. Adding a thrombotic 
surface by protein patterning on the glass slide is also a powerful technique (Figure 2-2C). 
Collagen, tissue factor, VWF, fibrinogen, and other prothrombotic proteins [45] have been 
used to initiate clotting within a defined area of the fluid channel, which helps to prevent 
nonspecific clotting elsewhere in the device, and focuses the location of the clotting data 
within a small area more easily monitored by fluorescent microscopy. Posts within flow 
channels (Figure 2-2D) are commonly used for localizing polymerized fibrous proteins 
(such as collagen [46,47] or VWF [19]) to provide a localized thrombotic surface on the 
side wall of a microfluidic device. Finally channel bifurcations (and trifurcations, Figure 
2-2E) at either the inlet or outlet enable control of fluid streamlines by introducing different 
fluids (such as calcium buffer and whole blood) to the device at different locations in the 
channel. This is because microfluidic flows have such low Reynolds numbers, so the flow 
is strongly laminar. In creative combinations, these common microfluidic features allow 
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the microfluidic platform to be versatile and useful for the study of hemostasis and 
thrombosis. 
  
27 
 
 
Figure 2-2: Common microfluidic features 
(A) Stenosis channel demonstrated in the impingement post device [19]. (B) Inlets and 
outlets can be plugged to change fluid flow paths. For example, in the stagnation point 
device [47], after collagen has been introduced into the device, the collagen inlets and 
outlet are plugged using flat syringe tips stuffed with putty to prevent air flow. (C) Collagen 
patterned on the glass slide to serve as a thrombotic surface in a flow channel [45]. (D) 
Posts in the side view microfluidic device [46] provide a place for collagen fibers to wrap 
around and immobilize. (E) A trifurcation inlet allows for fluid streamline control [36,48].  
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2.3 Device Design Considerations 
When designing a microfluidic device, there are two categories of common issues 
that need to be addressed with the design: channel size/position and fluid flow effects.  
In determining the size and position of channels on a microfluidic device, it is 
important to think about both the minimum allowable dimension size for the photomask 
printing and photolithography technique used. In the technique described above, details 
smaller than 15 µm do not appear in the final device reliably. Second, since data 
acquisition from a microfluidic device is usually done via fluorescent microscope, it is 
important to design the region of interest (where the data will be captured, e.g. platelet 
signal on a collagen patch) within as few microscope frames as possible, allowing 
optimization of both the image and time resolution of the data. For example, in the 
impingement post device discussed in Chapter 3, two adjacent channels are positioned 
such that both are visible in the same microscope frame without merging, allowing for 
higher throughput studies to be conducted. 
Though the COMSOL simulations discussed above are useful in designing 
channels, a few fluid issues arise in the experimental setup that don’t appear in the 
simulation. First, when fluid is pushed through the device by a syringe pump and has more 
than one possible path, the resistances over those paths will determine what fraction of 
fluid flow progresses through each. If the device is designed to have equal resistance over 
two paths, however, the pushed fluid will often proceed down one path due to small 
pressure instabilities in the fluid. Whenever tight control of the bifurcation of fluid is needed, 
it is useful to instead withdraw fluid from both outlets rather than pushing fluid from the 
inlet to overcome this pressure instability. Second, whenever the microfluidic device has 
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very small dimensions involved (e.g. a gap of <30 µm), there may be issues with clogging 
the device. Even if the dimension is large enough for all blood cells to pass through, 
aggregated debris from the air or filtered solution can clog and divert flow, or block the 
region of interest, leading to obscured data. To overcome this, be careful to filter all 
components in entering the device, and include a large number of replicates on one chip 
to help collect enough data from non-clogged channels only. 
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CHAPTER 3: PATHOLOGICAL VWF FIBERS RESIST TPA AND ADAMTS13 WHILE 
PROMOTING THE CONTACT PATHWAY AND SHEAR-INDUCED PLATELET 
ACTIVATION 
3.1 Introduction 
Severe coronary stenosis can cause extremely high shear rates, boundary layer 
detachment, and flow recirculation zones downstream of the stenosis [49]. Only when the 
stenosis exceeds ~75% occlusion does the flow resistance cause symptoms of angina 
[20]. Stenotic coronary flows can even create rare instances of fluid mechanical 
turbulence, especially during the deceleration phase of diastole [50]. At physiological 
arterial shear rates, von Willebrand Factor (VWF) is essential for platelet capture via 
glycoprotein Ib (GPIb) binding followed by adhesion stabilization via IIb3 binding to 
VWF [51]. However, in pathological flow conditions with shear rates exceeding 5000 s-1, 
VWF undergoes a complex coil-stretch transition to an extended conformation capable of 
association [52]. This complex aggregation process occurs both axially and laterally to 
form thick and long fiber bundles of greater than 100 μm in length [52]. The largest soluble 
VWF species above ~ 5 x 106 MW display remarkable platelet adhesivity [53,54] and may 
incorporate preferentially into VWF fibers. Additionally, extreme shearing flows in certain 
left ventricular assist devices cause an acquired von Willebrand’s Disease with associated 
bleeding risks [23].  
Distinct from unprocessed VWF fibers secreted acutely from endothelium 
[40,55,56], intrathrombic VWF fibers deposited during arterial thrombosis are likely derived 
from ADAMTS13-processed plasma [7]. Microfluidic devices have enabled studies of 
plasma-derived VWF unfolding and fiber formation on collagen at extreme shear 
conditions using small volumes of blood or plasma. Colace et al. [38] utilized a stenosis 
shaped microfluidic device to show VWF fiber formation and embolic VWF-platelet 
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aggregates on collagen mediated through GPIb and IIb3. Kragh et al. [57] also 
demonstrated self-assembly of VWF fibers on a collagen or VWF surface capable of rolling 
platelet aggregate formation under high shear rates. However, collagen in these VWF 
studies can have strong confounding effects on platelet function via activation of platelet 
GPVI. Other studies have coated the surfaces of glass slides [40] or microspheres [39] 
with plasma-derived VWF to explore how platelet thrombi formed on VWF-coated surfaces 
in response to shear. However, surface sorbed VWF from solution [54] lacks the structural 
and biomechanical attributes of VWF fibers formed from plasma at pathological shear. 
A stenotic microfluidic channel was designed with a micropost positioned in the 
middle of flow field to capture soluble VWF multimers as they experienced extreme shear 
rates within the device. Using a microfluidic design capable of generating fibrous VWF 
from plasma in the absence of collagen or endothelium, the unique mechanical and 
biological attributes of VWF fibers were investigated. We report the first determination of 
the VWF fiber elastic modulus, the role of VWF fibers in promoting contact pathway 
function, and the thrombolytic resistance of VWF fibers to tissue plasminogen activator 
(tPA). 
3.2 Materials and Methods 
3.2.1 Blood collection and preparation 
Whole blood was drawn from healthy volunteers who self-reported as free of any 
bleeding disorders or disease, as well as free of oral medication for at least 10 days. All 
blood was collected in accordance with the University of Pennsylvania’s Internal Review 
Board. Depending on the experiment, blood was anticoagulated with 5 mM EDTA (Sigma, 
St. Louis, MO) to chelate calcium, 100 μM D-Phe-Pro-Arg chloromethylketone (PPACK, 
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Haematologic Industries, Essex, VT) to inhibit thrombin and FXIIa, 1 μM apixaban to inhibit 
Factor Xa, and/or corn trypsin inhibitor (CTI, 4 μg/mL or 40 μg/mL) to inhibit Factor XIIa. 
GR144053 (2 M) was used in some experiments to inhibit IIb3. Platelet-free plasma 
(PFP) was generated by centrifugation of whole blood (300g, 10 min) to create platelet-
rich plasma (PRP), followed by PRP centrifugation (10,000g, 5 min) to create platelet-poor 
plasma (PPP), followed by PPP centrifugation (10,000g, 5 min). Trypsin (Life 
Technologies, Grand Island, NY), ADAMTS13 (R&D Systems, Minneapolis, MN), plasmin 
(Haematologic Technologies, Inc., Essex Junction, VT), and tPA (Abcam), and fluorogenic 
substrates FRETS-VWF73 (Anaspec, Fremont, CA) and Boc-VPR-MCA (R&D Systems) 
were also used. Anti-CD41 and anti-CD62P (BD Biosciences, San Diego, CA) are both 
PE labeled. Anti-Factor alpha XIIa antibody (Abcam) was labeled using an Alexa Fluor® 
647 Protein Labeling Kit (Life Technologies). FXII-deficient plasma (Haematologic 
Technologies, Inc.) was manufactured from normal citrated human plasma that was FXII 
immunodepleted to <1% activity. The antibody 14E11 was a kind gift from Dr. Andras 
Gruber (Oregon Health and Science University, Portland, OR). 
3.2.2 Device design and fabrication 
Microfluidic devices were fabricated out of polydimethylsiloxane (PDMS) 
(Ellsworth Adhesives) using previously described soft lithography techniques [44,58,59]. 
The device design consisted of a 500 μm channel that rapidly narrowed to a 60 μm wide 
stenosis region, which extended for 1000 μm before expanding again to a 500 μm wide 
channel. The channel height throughout the device was 60 μm. In the middle of the 
stenosis region, a 30-μm square micropost extended across the entire height of the 
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channel, providing a physical location for VWF fiber capture and growth without the use 
of collagen. 
3.2.3 Computational fluid dynamics 
Finite element simulations were conducted using COMSOL Multiphysics 
(Burlington, MA) to predict the plasma or blood flow profile (1.38 cP or 3.39 cP viscosity, 
respectively [60]) around the post, with and without a VWF deposit at steady flowrates of 
1 to 20 L/min. Computational fluid dynamics simulation provided wall shear rates at 
regions of interest: (1) average centerline wall shear rate in the stenosis region upstream 
of the post, which is a metric of the shear force on VWF in solution to extend into its active 
form before reaching the post, and (2) wall shear rate on the micropost, which is a metric 
of the extensional force on fibers that multimerize with other VWF already tethered on the 
post. 
3.2.4 Microfluidic flow experiments 
Devices were sealed to Sigmacote® (Sigma-Aldrich)-treated glass slides. The flow 
channels were blocked with 5% bovine serum albumin (BSA, Sigma-Aldrich) for 30 min 
before sample perfusion. Whole blood or PFP (under various specified anticoagulation 
conditions) were perfused through the device using a syringe pump (Harvard Apparatus, 
Holliston, MA). The microfluidic device was mounted on an Olympus IX81 inverted 
microscope equipped with a charge-coupled camera (Hamamatsu, Bridgewater, NJ). 
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3.3 Results 
3.3.1 Pathological shear rates generate fibrous VWF from plasma on a capturing 
micropost 
A PDMS microfluidic device with 8 individual lanes was vacuum-sealed to glass where 
each lane converged stenotically to a 60 m wide x 60 m high flow path that then 
impinged on a 30-m square micropost (Figure 3-1A-B). Fluid streamlines were visualized 
with 10 μm fluorescent beads (5 μL/min) revealing the computationally-expected flow 
stagnation points on the front and back of the micropost (Figure 3-1C-D). For a flow rate 
of 5 L/min, wall shear rate increased from 0 at the front centerline stagnation point to 
>10,000 s-1 at the front corners of the micropost, resulting in a wall shear rate gradient of 
~3.33 x 106 s-1/cm. The peak wall shear rates along the side walls of the micropost were 
calculated at 20,000 s-1 for a flow rate of 5 L/min (Figure 3-1E). As plasma impinges and 
flows around the post, a rapidly increasing extensional force is expected to help to orient 
fibers to maximize their contact with the post, increasing the probability of a VWF fiber 
sticking. Perfusion of EDTA-PFP resulted in VWF fiber formation at 5000, 8000, and 
10000 s-1 upstream centerline wall shear rate (Figure 3-2A). The thickness of the fibers at 
5 min increased 5-fold (p<0.01) from 2.5 μm to 12.5 μm as the wall shear rate increased 
from 5000 to 10000 s-1 (Figure 3-2B). Flow-aligned VWF fibers were stretched in the 
direction of flow as they formed since an acute reduction in flow triggered an observable 
retraction. To examine the elastic properties of VWF, a small post-attached single VWF 
fiber was formed at 10000 s-1 (13.7 L/min) and then interrogated mechanically by 
alterations in the prevailing flow rate. Once the small fiber formed from plasma, the flow 
was switched to HBS and reduced to 4 μL/min and HBS was perfused over the tethered 
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VWF fiber. The flow rate was increased stepwise from 4 to 13 L/min, allowing the fiber 
to equilibrate at each flow rate before measuring its length (Figure 3-2C). The wall shear 
stress and total force on the surface of the fiber as it was stretched was estimated with an 
axial annular flow approximation over a cylindrical fiber. Assuming the volume of the fiber 
was conserved over the experiment, the length of the fiber after each stretch was used to 
determine its new diameter. By integrating the drag force per length over the entire length 
of the fiber, the total stress on the fiber was calculated, assuming the initial 4 μL/min fiber 
as “relaxed” for the purpose of comparison to the “stretched” forms of the fiber under 
higher flow rates. Through this estimation, the calculated elastic modulus of fibrous 
plasma-derived human VWF was ~50 MPa (Figure 3-2D), quite similar to the fibrin fiber 
elastic modulus in FXIIIa-crosslinked plasma clots [61]. 
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Figure 3-1: Microfluidic device design and characterization 
(A) Stenosis-shaped channel with a small post located in the middle of flow. (B) 
Macroscopic device design allows for multiple channel VWF fiber generation. (C) 
Fluorescent beads were perfused past the post and imaged with a 25 ms exposure to 
visualize streamlines within the device. (D) COMSOL-simulated streamlines depicting 
diverging flow upstream of the post. (E) Wall shear rate heat map flow for a flow rate of 5 
μL/min. 
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Figure 3-2: VWF fiber characteristics and mechanical properties 
(A) Representative immunofluorescent images of VWF fibers that were generated by 
flowing EDTA PFP at 5000, 8000, and 10000 s-1 upstream wall shear rate for 5 min from 
initial fiber capture. (B) Average fiber width was measured at 30 μm below the post at each 
shear rate. (C) A single VWF fiber was captured on the post by flowing EDTA PFP at 5000 
s-1 for 30 s from initial fiber capture. The fluid was then switched to HBS to prevent 
additional VWF fiber growth and the flow was reduced to 4 μL/min. The flow rate was 
increased stepwise and the fiber was allowed to equilibrate between steps. (D) Stress-
strain plot for the single VWF fiber in C. Stress was calculated by assuming axial annular 
flow around the fiber to calculate the drag force on the fiber. Strain was calculated 
assuming the 4 μL/min case was “at rest” and each subsequent flow rate as stretched 
forms at constant fiber volume. 
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3.3.2 Fibrous VWF is non-amyloid, tPA-resistant, but plasmin-sensitive 
In order to further characterize the VWF fibers produced by micropost capture, 
various proteases/surfactants were assessed. Both 0.25 % trypsin and 2% SDS quickly 
dissolved fibrous VWF (Figure 3-3A-B), demonstrating that insoluble VWF fibers were 
non-amyloid. In contrast, 30 mM N-acetylcysteine was not able to dissolve already formed 
VWF fibers (not shown). However, when ADAMTS13 (50 nM) was added to plasma and 
perfused over VWF fibers, no observable degradation took place at 10000 s-1 within 480 
s (Figure 3-3C). ADAMTS13 activity was confirmed with the fluorogenic substrate FRETS-
VWF73. VWF fibers (formed from plasma treated with apixaban and PPACK to prevent 
any fibrin incorporation) were resistant to 100 nM tPA in apixaban/PPACK-treated plasma 
(Figure 3-3D) demonstrating that VWF does not serve as a cofactor to enhance tPA 
activity toward plasminogen. However, 1 μM plasmin readily dissolved fibrous VWF fibers 
formed from EDTA-treated PFP in 40 s (Figure 3-3E), a result consistent with that 
observed for trypsin. Both plasmin and trypsin are fairly non-specific peptidase family S1 
(chymotrypsin family, clan PA) members [62]. Also, soluble VWF is a known substrate for 
plasmin [63].  
3.3.3 Fibrous VWF accumulates procoagulant factors to drive fibrin formation 
To analyze the role of VWF in the function of the contact pathway, the 
polymerization of fibrin was monitored on the surface of VWF fibers created under different 
conditions. To isolate the role of VWF from the effect of platelets, platelet-free plasma 
(PFP) was used for both fibrous VWF formation and the subsequent coagulating flow over 
the VWF. When Factor XIIa was only weakly inhibited with 4 μg/mL CTI in recalcified 
citrated PFP that was perfused over VWF fibers previously made in the presence of EDTA, 
39 
 
fibrin began polymerizing on the surface of the VWF fibers within 7 min at an upstream 
wall shear rate of 1500 s-1 (Figure 3-4A). 
However, it was unclear whether: (case 1) the VWF fibers themselves were 
initiating the contact pathway as a surface activator of Factor XII, (case 2) the VWF fibers 
had accumulated contact pathway factors as they formed (EDTA does not inhibit FXIIa 
generation or thrombin activity), or (case 3) fibrin fibers were forming upstream in the 
device in low CTI plasma and were simply accumulating on the VWF. Surface-adsorbed 
VWF did not initiate significant contact activation in a well plate thrombin assay (Figure 
3-5). When the low CTI-plasma perfusion experiment was repeated with an empty post, 
no fibrin was formed or captured (Figure 3-4B). Similarly, when repeating the experiment 
with micropost-captured fibrillar collagen in place of the VWF fibers, no fibrin formed on or 
was captured by the collagen fibers (equine fibrillary collagen type 1, Chronopar, 
Chronolog) (Figure 3-4C). The shear rate of 1500 s-1 was too low for the plasma VWF to 
form massive VWF fibers on the collagen. These two results demonstrated that fibrin 
polymerization occurred on the VWF fibers in Figure 3-4A conditions and was not simply 
forming upstream and capturing on the post or fibers (case 3). To distinguish case 1 (FXIIa 
generation) from case 2 (contact factor accumulation) the previous experiment was 
repeated with VWF fibers generated from fully inhibited plasma (apixaban/PPACK/high-
CTI/EDTA). By inhibiting these active factors during VWF fiber multimerization, FXIIa 
activation and subsequent thrombin and fibrin generation would need to initiate on that 
VWF surface during perfusion of low CTI plasma. However, no fibrin formed on the fully 
inhibited fibers (Figure 3-4D), eliminating case 1 and demonstrating case 2 where active 
coagulation factors in low CTI plasma were concentrated in the VWF fiber as it formed. 
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No extrinsic pathway participation of tissue factor or FVIIa function on platelets can occur 
in these conditions [64].  
To further investigate the possibility of upstream fibrin formation, we measured 
thrombin activity in calcium-containing plasma formed in the well prior to entrance into the 
microfluidic channel. Using the fluorogenic thrombin substrate boc-VPR-MCA, CTI-treated 
recalcified citrated plasma did not generate any detectable thrombin in 20 min. With no 
thrombin present in the upstream reservoir under the conditions of the experiment, fibrin 
would not be able to polymerize upstream. We conclude that fibrin was generated on the 
VWF itself from local thrombin within the VWF, rather than deposition of fibrin formed 
upstream.  
Additionally, VWF fibers were formed at pathological shear from EDTA-treated 
normal plasma or FXII-deficient plasma and then immunostained with fluorescent anti-
FXII(a) in HBS. FXII(a) immunofluorescence was detected on VWF fibers from EDTA-
plasma, but not on FXII-deficient plasma (Figure 3-6). When FXIa generation was inhibited 
by 14E11 antibody (an antibody that binds FXI and prevents its activation by FXIIa) in the 
plasma used to generate VWF, no fibrin formed subsequently on the deposited VWF fibers 
when recalcified plasma was perfused (Figure 3-7). This experiment demonstrated that 
FXIa (and its co-localized activator, FXIIa as seen in Figure 3-6) were localized on the 
VWF during fiber formation under pathological flow. 
A “bystander effect” was observed when fibrin was allowed to form on the VWF 
before perfusion of tPA. Though tPA was not able to convert plasminogen to plasmin on 
the surface of VWF fibers, plasmin generated by tPA on the surface of fibrin (co-localized 
with the VWF fiber) was able to cleave nearby VWF (Figure 3-8). 
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Figure 3-3: Sensitivity of VWF fibers to various proteases and surfactants 
(A) VWF fibers were generated using EDTA inhibited PFP at 10000 s-1 for 5 min from initial 
fiber capture. VWF was then labeled using polyclonal fluorescent anti-VWF antibody in 
HBS, and then washed with HBS for 2 min to reduce background. When 0.25% trypsin 
solution was perfused over the VWF at 10000 s-1, the fibers were digested in 10 s. (B) 
When 2% SDS solution was perfused over the VWF at 10000 s-1, the fibers were dissolved 
in 80 s. (C) VWF fibers were generated using apixaban and PPACK inhibited PFP at 
10000 s-1 for 5 min from initial fiber capture. VWF was then labeled using polyclonal 
fluorescent anti-VWF antibody in HBS, and then washed with HBS for 2 min to reduce 
background. The shear rate was reduced to 1500 s-1 and apixaban and PPACK inhibited 
PFP with 50 nM ADAMTS13 was perfused over the fibrous VWF for 480 s. (D) VWF fibers 
were generated in the same way as C. The shear rate was reduced to 1500 s-1 and 
apixaban and PPACK inhibited PFP with 100 nM tPA was perfused over the fibrous VWF 
for 300 s. (E) VWF fibers were generated in the same way as A. When 1 μM plasmin in 
HBS was perfused over the VWF fibers at 1500 s-1, the fibers were digested in 40 s. 
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Figure 3-4: Fibrous VWF provides a surface for coagulation via contact pathway 
(A) VWF fibers were generated using EDTA PFP at 10000 s-1 for 5 min from initial fiber 
capture. VWF was then labeled using polyclonal fluorescent anti-VWF antibody in HBS, 
and then washed with HBS for 2 min to reduce background. The shear rate was reduced 
to 1500 s-1 and recalcified low CTI (4 μg/mL, LCTI) citrated PFP labeled with fluorescent 
anti-fibrin antibody was perfused over the fibrous VWF for 20 min. (B) No VWF fibers were 
generated on the post before perfusion of recalcified LCTI citrated PFP labeled with 
fluorescent anti-fibrin antibody at 1500 s-1 for 20 min. No fibrin formed on the post. (C) 10 
μg/mL collagen type 1 solution in HBS was perfused over the post for at 10000 s-1 until 
the collagen fibers were approximately the same size as the previous VWF fibers. 
Recalcified LCTI citrated PFP labeled with fluorescent anti-fibrin antibody was then 
perfused over the collagen fibers at 1500 s-1 for 20 min. No fibrin formed on the collagen 
or post. (D) VWF fibers were generated using 40 μg/mL CTI, 1 μM apixaban, 100 μM 
PPACK, and 5 mM EDTA inhibited PFP at 10000 s-1 for 5 min from initial fiber capture. 
VWF was then labeled using polyclonal fluorescent anti-VWF antibody in HBS, and then 
washed with HBS for 2 min to reduce background. The shear rate was reduced to 1500 s-
1 and recalcified LCTI citrated PFP labeled with fluorescent anti-fibrin antibody was 
perfused over the fibrous VWF for 20 min. No fibrin formed on the inhibited VWF fibers. 
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Figure 3-5: Sorbed VWF does not initiate thrombin generation through the contact 
activation pathway  
Recombinant VWF (100 μg/mL), 5% BSA, or HBS incubated in a 384 well plate for 4 hours 
to allow for protein adsorption. These surfaces were then washed with PPACK and 
apixaban in HBS, followed by an HBS wash. Calcium buffer (15 mM final concentration) 
with Boc-VPR-MCA was added to each well as a fluorescent thrombin substrate, and 
kaolin was added to the sorbed HBS well as a known potent contact pathway activator.  
PFP inhibited with 4 μg/mL CTI and citrate was then added to each well and mixed. 
Substrate fluorescence was measured by a plate reader (Fluoroskan) every 15 seconds.  
Average fluorescent intensity and standard deviation was calculated (n=5). 
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Figure 3-6: FXII(a) localized on fibers 
VWF fibers were formed at pathological shear from EDTA-treated plasma or FXII-deficient 
plasma and immunostained with anti- αFXII(a).  VWF fibers formed from normal plasma 
displayed FXII(a) immunostaining.  No staining was detected on VWF fibers formed from 
FXII-deficient plasma. 
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Figure 3-7: Fibrin formation on VWF fibers was blocked by anti-FXI antibody (14E11) 
which had been present during VWF fiber formation 
The 14E11 antibody, which blocks FXIa formation by FXIIa, was added to EDTA plasma 
during VWF fiber generation, followed by perfusion of low CTI, recalcified plasma (lacking 
14E11) over the fibers. No fibrin formed after 20 min perfusion, demonstrating that FXIa 
was deposited on the VWF fibers as they were generated. 
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Figure 3-8:  Bystander effect allowed fibrin/tPA-dependent generation of plasmin 
which then led to subsequent solubilization of VWF fibers 
Low CTI recalcified PFP was perfused over VWF fibers made with EDTA PFP. After fibrin 
had formed on the VWF fibers, 100 nM tPA was added to low CTI recalcified PFP and 
perfused over the fibrin and VWF. Both the fibrin and VWF were cleaved by 150 s.  
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3.3.4 Platelets roll and adhere on VWF fibers but pathological shear drives P-
selectin display 
Whole blood anticoagulated with PPACK/apixaban and treated with fluorescent 
anti-CD41 and anti-CD62P was perfused over fibrous VWF (formed from 
PPACK/apixaban-treated plasma) at 1500 and 3000 s-1. Platelets attached, rolled, and 
firmly bound to the fibrous VWF at both shear rates (Figure 3-9), demonstrating the 
previously observed behaviors seen on endothelial anchored VWF [65], immobilized 
plasma VWF [66,67] and fibrous VWF on collagen [38]. Additionally, platelets arrested on 
the fibrous VWF at either shear rate, but only displayed P-selectin at 3000 s-1 (Figure 
3-9A), consistent with a role for fibrous VWF supporting shear-induced platelet activation 
(SIPA). The wall shear rates seen on the surface of fibers (~5000 s-1) were obtained with 
an upstream approach wall shear rate of 1500 s-1 (Figure 3-10). GR144053 at 2 μM to 
inhibit IIb3 prevented platelet arrest on the VWF fibers (Figure 3-9B). Therefore, fibrous 
VWF was a platelet activating surface under physiological arterial shear rates and a 
cofactor for SIPA at pathological shear rates to induce P-selectin display. 
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Figure 3-9: Platelets adhere to and activate on fibrous VWF 
(A) VWF fibers were generated using apixaban and PPACK inhibited PFP at 10000 s-1 for 
5 min from initial fiber capture. VWF was then labeled using polyclonal fluorescent anti-
VWF antibody in HBS, and then washed with HBS for 2 min to reduce background. The 
shear rate was reduced to either 1500 s-1 or 3000 s-1 and apixaban and PPACK inhibited 
whole blood labeled with fluorescent anti-CD41 (platelets) and fluorescent anti-CD62P (P-
selectin) was perfused over the fibrous VWF for 10 min. (B) VWF fibers were generated 
and labeled using the same procedure as A. The addition of GR 144053 to the whole 
blood described in A resulted in total inhibition of firm platelet adhesion to the VWF fibers. 
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Figure 3-10: Local shear stress on surface of fibrous VWF does not predict location 
of activated platelets 
The fluorescent signal from the VWF from Figure 3-9 was traced and modeled in COMSOL 
to approximate the three-dimensional structure of VWF in the device. Device shear was 
set to 1500 s-1 to simulate the conditions for the platelet activation experiments to 
determine the shears experienced by platelets at positions along the surface of VWF.  
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Figure 3-11: Chelation of calcium and inhibition of calcium-dependent ADAMTS13 
activity in plasma does not result in a significant differences in fiber size 
Apixaban/PPACK plasma with or without EDTA was used to form VWF fibers at a shear 
rate of 10000 s-1. Since ADAMTS13 requires calcium, we found no significant influence of 
ADAMTS13 in VWF fiber formation, an expected result since plasma ADAMTS13 had 
already processed the soluble VWF multimers in the plasma used to form the fibers. 
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3.4 Discussion 
By designing a microfluidic device capable of capturing multimerized VWF fibers in 
pathological shear flow, we were able to investigate mechanical, biochemical, and 
biological properties of fibrous VWF. The lack of collagen in the VWF capture method of 
this device allows the role of VWF to be examined without collagen present, and may be 
more representative of the VWF-rich regions of thrombotic clots seen in the work of Le 
Behot et al. [7], where VWF incorporated into the top region of nearly occlusive thrombi 
and was not directly bound to subsurface collagen [7]. The determination of the VWF fiber 
elastic modulus is potentially quite useful for whole clot mechanical modeling, particularly 
in studying thromboembolism [68,69]. Another advantage to this approach is that the VWF 
fibers are formed under single-pass shear flow, which is a more physiologically relevant 
condition than continuous exposure in a cone and plate viscometer or vortexing assays 
[70,71]. VWF aggregates produced in a cone and plate viscometer have previously been 
shown to partially dissociate after treatment by SDS [72], but we have shown that fibrous 
VWF made under elongational flow also dissociates in response to SDS. This single-pass 
flow approach demonstrates that the sensitivity of VWF fibers to trypsin, SDS, and plasmin 
does not require long incubation times to achieve substantial degradation of the fibers. 
The focus of this study is on human plasma VWF, which unlike VWF secreted by 
endothelial cells, is made up of subunit fragments resulting from processing of endothelial 
VWF by ADAMTS13 [73,74]. For endothelial released ultra-large VWF, cleavage by 
ADAMTS13 regulates the release and size of VWF multimers by cleaving the A2 domain 
of VWF to release it into the blood stream [74]. As a result, the fibers observed in this 
study, and potentially those in the high shear exposed regions of large thrombi, would 
potentially have resistance to ADAMTS13 due to a lower fraction of structurally exposed 
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A2 domains for cleavage of large VWF fibers. The ADAMTS13 sensitivity of VWF fibers 
in the absence of platelets has not been previously studied [75]. Although soluble VWF 
multimers have been shown to reduce in size in the presence of ADAMTS13 and shear 
[76], the ability of ADAMTS13 to cleave insoluble VWF fibers was observed in this assay 
to be undetectable. The effect of calcium, and therefore endogenous calcium-dependent 
ADAMTS13 activity, on the formation size of VWF fibers was found to be insignificant 
(Figure 3-11), consistent with the fact that the plasma VWF multimers incorporated into 
the fiber at pathological shear rate were already processed by ADAMTS13. Distinct from 
observations of acutely released ULVWF from stimulated endothelium, the massive VWF 
fibers formed at high shear from processed plasma VWF were insensitive to ADAMTS13. 
In typical thrombolytic therapy, tPA is used to dissolve fibrin rich thrombi by 
converting plasminogen into plasmin on the surface of fibrin, which then degrades fibrin 
[77]. In occlusive thrombi, degradation of clot-integrated VWF by plasmin could synergize 
with the cleavage of fibrin to contribute to overall thrombolysis. Both trypsin and plasmin 
can reduce the average multimer size of purified soluble VWF [63]. We show these 
activities are maintained on the insoluble fibrous form of VWF generated from plasma. 
However, fibrous VWF was not a cofactor for tPA. The resolution of VWF in an arterial 
occlusion during thrombolytic therapy with tPA would require the transfer of plasmin from 
degrading fibrin to the fibrous VWF without inhibition by soluble or fibrin-linked antiplasmin.  
Coagulation on the surface of fibrous VWF could play an important role in 
propagating clot growth to occlusion in severe thrombosis. The role of the contact pathway 
in arterial thrombosis has received considerable attention recently [12–14]. Because 
collagen and apixaban/PPACK/high-CTI/EDTA inhibited VWF fibers do not lead to fibrin 
formation, we conclude that active FXIIa or FXIa accumulated on VWF fibers while they 
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formed. Endothelial cell-anchored ultra-large VWF has been shown to cause localization 
of other blood proteins on VWF [78]. Coagulation factor accumulation could potentially 
lead to a second wave of coagulation at the top region of a thrombus, leading to vessel 
occlusion. 
Though it is well established that platelets bind to and roll along endothelial bound 
multimeric VWF [65], it had not previously been observed on multimeric plasma VWF in 
the absence of collagen as a confounding platelet stimulus [38]. Rolling adhesion occurs 
through GPIbα, and firm adhesion occurs through IIb3, but platelet activation that occurs 
when bound to VWF is thought to do so through GPIb caused by GPIb clustering on 
the surface of platelets [79]. The resulting proximity to the VWF fibers allows the slower 
but long-lived IIb3 bond to take stably take hold of the platelet. Outside-in signaling via 
GPIb or αIIbβ3 could also contribute to platelet activation through a mechano-sensitive 
mechanism when bound to VWF [80]. Only if prevailing shear rates are pathological can 
the shear forces on the platelet drive P-selectin exposure (Figure 3-9). In summary, we 
report that fibrous VWF formed under conditions of pathological stenotic flow are non-
amyloid, plasmin sensitive but tPA-resistant, procoagulant through accumulation of 
contact pathway factors, and substrates for SIPA at pathological shear rates. 
3.5 Summary 
Under severe stenotic conditions, von Willebrand Factor (VWF) multimerizes into 
large insoluble fibers at pathological shear rates. Our objective was to evaluate the 
mechanics and biology of VWF fibers without the confounding effects of endothelium or 
collagen. Within a micropost-impingement microfluidic device, >100 m long VWF fibers 
multimerized on the post within 10 min using EDTA-treated PFP perfused at wall shear 
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rates >5000 s-1. VWF fiber thickness increased to >10 m by increasing shear rate to 
10,000 s-1. In a stress-strain test, fibrous VWF had an elastic modulus of ~50 MPa. The 
insoluble VWF fibers were non-amyloid since they rapidly dissolved in trypsin, plasmin, or 
2% SDS, but were resistant to 50 nM ADAMTS13 or 100 nM tPA in plasma. Following 
fiber formation, perfusion of low corn trypsin inhibitor (CTI)-treated (4 g/ml), recalcified 
citrated plasma at 1500 s-1 caused fibrin formation on the VWF fibers, a result not observed 
with purified type 1 collagen or a naked micropost. During VWF fiber formation, contact 
pathway factors accumulated on VWF since the use of EDTA/PPACK/apixaban/high CTI-
treated PFP during VWF fiber formation prevented subsequent fibrin production from low 
CTI, recalcified citrated PFP. When PPACK-inhibited whole blood was perfused over VWF 
fibers, platelets rolled and arrested on the surface of VWF, but only displayed P-selectin 
if prevailing shear rates were pathological. Platelet arrest on VWF fibers was blocked with 
IIb3 antagonist GR144053. These observations reveal VWF fiber-contact pathway 
crosstalk and new mechanisms of thrombolytic resistance in the hemodynamic setting of 
acute myocardial infarction. 
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CHAPTER 4: THROMBI PRODUCED IN STAGNATION POINT FLOWS HAVE A 
CORE-SHELL STRUCTURE 
4.1 Introduction 
Platelet response at sites of vascular injury is crucial for hemostasis. However, 
excessive platelet aggregation and thrombin generation at sites of atherosclerotic plaque 
rupture can lead to occlusive thrombi that drive acute coronary syndromes. In regions 
where vessel geometry gives rise to flow recirculation and stagnation point flows, the risk 
of endothelial dysfunction and thrombosis may be enhanced. Stagnation point flows occur 
at several locations of diseased vasculature, including in vessel bifurcations and at 
reattachment points downstream of stenotic geometries [81]. Thrombosis at stagnation 
points have been observed in a number of vessel geometries, particularly in preferred 
sites of atherosclerotic lesions, including parts of the aorta [82] and carotid-posterior 
communicating artery junction [83]. Because this unique flow pattern results in unusual 
platelet and agonist transport and fluid forces compared to typical vessel flow, it is 
important to understand how these factors affect clot growth and structure. 
Stagnation point flow has been shown to alter endothelial cell biology, shape, and 
density. Human atherosclerosis develops preferentially in low shear stress, oscillatory, 
and reversing flow regions of arteries, including adjacent to stagnation points, where lipids 
tend to deposit in the arterial wall [84]. Endothelial cells in these regions also tend to be 
less densely packed and less aligned compared to the high density and elongated 
endothelial cells found in regions of high and unidirectional wall shear stress, as seen both 
in in vitro disturbed flow assays and in vivo atherosclerotic studies [85,86]. These 
conditions lead to the development and worsening of plaques in humans [86]. 
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In these regions, any gap in the endothelium or plaque rupture can expose a 
thrombogenic surface to the blood. Since blood flow at the stagnation point is zero, there 
is potentially a longer residence time for platelets to bind to any exposed collagen, as well 
as decreased convective transport of agonists leading to more activated platelets near 
stagnation points. 
Previously, stagnation point thrombosis has been examined primarily using radial 
flow geometries on either synthetic or cell surfaces. Petschek and colleagues [87] 
examined the formation of platelet clots from canine blood on glass and polyurethane 
surfaces in a stagnation point geometry with radial flow. Reininger and colleagues [88] 
examined radial stagnation point flows of platelet-rich plasma on intact endothelial cells, 
and found that adhesion only occurred when platelets were pre-stimulated with ADP. 
David et al. [89] developed a mathematical and numerical model for the adhesion of 
platelets in stagnation point flow using a shear dependent reaction rate, and found that 
the maximum platelet flux occurs downstream of the stagnation point, rather than at it. In 
these previous experimental studies, a radially-directed and decelerating flow developed 
from the stagnation point. In these geometries, flow velocity drastically decreases as it 
moves radially. However, this radial flow is unlike the flow field expected at the 
reattachment point distal to a stenosis. 
In this study, a stagnation point microfluidic device was developed with the ability to 
localize collagen and TF to a scaffold region, which was then subject to a perpendicular 
flow of whole blood impinging on the thrombotic collagen/TF surface. We demonstrate the 
ability to initiate and grow thrombi at a stagnation point using human whole blood and 
examine their structures under different flow and biochemical conditions. 
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4.2 Materials and Methods 
4.2.1 Blood collection and preparation 
Human blood was obtained from healthy donors who self-reported as free of any 
bleeding diseases or disorders, as well as free of oral medication for at least 10 days. All 
blood was collected in accordance with the University of Pennsylvania’s Internal Review 
Board. Blood was anticoagulated with 40 μg/mL corn trypsin inhibitor (CTI, Haematologic 
Technologies Inc., Essex Junction, VT) to inhibit factor βXIIa. Depending on the 
experiment, PE-labeled anti-CD61 and anti-CD62P (BD Biosciences, San Diego, CA, 
USA) were used to label platelets and P-selectin, respectively. FITC-conjugated anti-von 
Willebrand Factor antibody (Abcam, Cambridge, MA, USA) was used to label von 
Willebrand Factor (VWF), and anti-fibrin antibody (gift from M. Poncz, Children’s Hospital 
of Philadelphia) was used to label fibrin. N-acetylcysteine (NAC, Sigma Aldrich) and anti-
CD42B (anti-GPIb antibody, Abcam) were also added to whole blood before perfusion in 
certain experiments, where indicated.  
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Figure 4-1: Microfluidic device design and characterization 
(A) The stagnation point device contained 3 ports for loading collagen into the scaffold 
region, and 3 ports for controlling blood flow. (B) At the region of interest, the inlet blood 
flow impinged on a collagen scaffold surface on the side wall before diverging to the blood 
outlets. All channels were 250 μm wide and 60 μm deep. Posts within the scaffold region 
were 50 μm in diameter. (C) COMSOL-simulated streamlines depict impinging flow at the 
stagnation point at the center of the collagen scaffold. 
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4.2.2 Microfluidic device design and fabrication 
Microfluidic devices were fabricated out of polydimethylsiloxane (PDMS, Ellsworth 
Adhesives, Germantown, WI, USA) using previously described soft lithography techniques 
[44,58,59]. The stagnation point device (Figure 4-1A) consisted of two perpendicular 
channels with 250 μm width and 60 μm height that intersect at the scaffold region (Figure 
4-1B). Collagen inlets (labeled Ci) were positioned on either side of the blood inlet channel 
(labeled Bi), and the collagen outlet used to pull collagen into the scaffold region (labeled 
Co) was located behind the scaffold posts. The scaffold was designed with post array (Dpost 
= 50 μm) spaced 20 μm apart with an opening narrowing from L = 250 μm at the channel 
interface to L = 50 μm at the outlet (Figure 4-1B). The posts positions were optimized for 
uniformly loading collagen fibers. [46] 
4.2.3 Computational fluid dynamics 
Finite element simulations were conducted using COMSOL Multiphysics 
(Burlington, MA, USA) to predict the blood flow profile and shear rates with and without 
clot formation on the collagen/TF surface at inlet flow rates of 10 and 100 μL/min. The 
model shown (Figure 4-2) was not dependent on hematocrit and was a computational fluid 
dynamics model using a constant blood fluid density of 1060 kg/m3 and a Newtonian blood 
viscosity of 3.39 cP [60]. The collagen/TF surface was approximated as an impermeable 
wall such that all fluid impinging on the collagen/TF surface exited the device via the two 
blood outlets (Figure 4-1B).  
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4.2.4 Microfluidic flow experiments 
Devices were secured to the surface of Sigmacote® (Sigma-Aldrich, St. Louis, MO, 
USA)-treated glass slides using a vacuum pump, and the channels were coated with 10% 
bovine serum albumin (BSA) for 30 minutes. Polymerized fibrillar collagen was prepared 
by incubating collagen (3 mg/mL monomeric human type I, Vitrocol, Advanced BioMatrix, 
Inc., Carlsbad, CA, USA), 10X PBS, and 90 mM NaOH in an 8:1:1 ratio at 37°C overnight. 
Lipidated tissue factor (Dade® Innovin® recombinant human TF, VWR Corp, Radnor, PA) 
was prepared as previously described [90] and mixed with the polymerized collagen in a 
1:20 ratio by volume. The solution was incubated for 10 minutes at room temperature. To 
load collagen into the device scaffold, 2 μL of the collagen solutions were pulled into the 
scaffold via the two “collagen in” ports (Figure 4-1A). 5 mM Ca2+ buffer was then rinsed 
through the channels to remove any collagen outside of the scaffold region. The final 
tissue factor surface concentration was ~1 molecule/μm2. The collagen in and out ports 
were plugged to prevent additional flow during blood perfusion. The blood flow was 
controlled via syringe pump (Harvard Apparatus, Holliston, MA, USA) connected to the 
two “blood out” ports to withdraw blood from the inlet port to the two outlet ports. 
Microfluidic devices were mounted on an Olympus IX81 inverted microscope (Olympus 
America, Center Valley, PA, USA) equipped with a charge-coupled device camera 
(Hamamatsu, Bridgewater, NJ, USA). Thrombus growth was quantified by measuring the 
clot height at 10 evenly spaced positions across the collagen/TF surface at each time 
point. Average clot height and standard deviation were calculated for each condition and 
time point across multiple replicates. 
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4.3 Results 
4.3.1 Microfluidic device produces stagnation point flows with controllable shear 
gradients 
A microfluidic device was designed to create a flow pattern that produced a 
stagnation point on a collagen/TF surface, while fluorescently imaging local clot formation 
at and near the stagnation point. By designing the device to have the collagen surface on 
a side-wall, it enabled direct monitoring of the clot growth along the growth axis as well as 
morphological differences along the clot height. After collagen/TF was loaded into the 
device (Figure 4-2A), the collagen inlets and outlets were plugged and the flow path 
consisted solely of the blood inlet channel and the two blood outlet channels. Initially, the 
calculated wall shear rate is zero at the impingement point and increases monotonically 
to the outlet shear rate far from the stagnation point for 3 different inlet flow rates of 10, 
50, and 100 μL/min (Figure 4-2B). Over the collagen/TF region, the shear rate increases 
outward from the stagnation point in a roughly linear gradient that significantly increases 
as flow rate increases (∇γw = 1.2 s-1/μm at 10 μL/min and 12.5 s-1/μm for 100 μL/min). This 
setup allows for the examination of both low shear gradients (10 µL/min) and high shear 
gradients (100 µL/min) over the same thrombotic zone in this flow geometry. The inlet flow 
rates of 10 and 100 μL/min resulted in inlet channel shear rates of 100 s-1 and 1000 s-1, 
respectively. 
As a thrombus grows on the collagen/TF surface, the local wall shear rate profile 
will change due to differing local fluid velocities. To simulate this, a 50-µm high rounded 
thrombus was added over the thrombotic surface (Figure 4-2C). This change in flow 
geometry had two effects on the wall shear rates (Figure 4-2D). First, the shear gradients  
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Figure 4-2: Simulated wall shear rate profiles evolve during clot growth 
(A, B) Prior to clot formation, the wall shear rate increased approximately linearly 
throughout the collagen region before plateauing at a final shear rate in both side 
channels. Higher inlet flow rates led to steeper wall shear rate gradients over the collagen 
surface. (C, D) As the clot grew, the shear gradients surrounding the stagnation point 
steepened in the collagen region. The final wall shear rates in the side channels remained 
the same. 
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immediately surrounding the stagnation point steepened. Second, the monotonic behavior 
of the shear rate disappeared as flow both accelerated and decelerated near the surface 
of the thrombus due to the influence of the constraining microfluidic boundaries. Even 
within the small area around a stagnation point, regions of both high and low shear 
rates/gradients as clots grow were observed in the simulation. 
4.3.2 Stagnation point thrombi display a core-shell architecture 
Whole blood anticoagulated with CTI and treated with fluorescent anti-CD61, anti-
CD62P, and anti-fibrin (labeling platelets, P-selectin, and fibrin, respectively) was perfused 
through the device at 10 or 100 µL/min impinging upon the collagen/TF surface, where it 
was allowed to clot for 8 minutes (Figure 4-3). Platelets immediately began binding to the 
thrombotic surface on either side of the stagnation point, but did not adhere at the 
stagnation point itself. This phenomenon, which has been previously observed in radial 
flows [91], was potentially due to decreased platelet flux at in the centerline of the flow. 
A difference in thrombus morphology was observed between the lower and higher 
inlet flow rates. At the low flow rate, the thrombi were noticeably dendritic in structure, with 
gaps between each deposit where platelets were not able to easily access. In contrast, 
thrombi formed at the high flow rate were relatively uniform across the length of the 
collagen. This difference was likely due to thrombus remodeling in response to 
hemodynamic forces, where higher flow rates lead to strong shear gradients that deform 
and densify the platelet masses, leading to a more evenly spread thrombus. It appears 
that the dendritic structure of the thrombi results from buildup rather than embolization. 
Because the thrombotic surface has some roughness, there is early roughness in the 
location of platelet deposits which propagate as additional platelets  
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Figure 4-3: Core-shell thrombus morphology observed at low and high shear rates 
Perfusion of high CTI whole blood at an inlet flow rate of 10 μL/min on a collagen/TF 
surface resulted in the formation of irregular heterogeneous platelet (green) clots. 
Significant fibrin formation (red) and platelet activation (blue, observed via P-selectin 
labeling) demonstrated a core-shell architecture as previously described [92]. At an inlet 
flow rate of 100 μL/min, the same core-shell architecture was seen, but in a much denser 
and regular clot shape. 
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adhere to the deposits. Once they take on a dendritic structure, there is poor flow between 
the dendrites, resulting in low platelet delivery in those gaps. After 8 minutes, clots formed 
at 10 and 100 μL/min measured 44.9 μm and 37.6 μm in average height above the 
collagen/TF surface, respectively. 
The clots formed at both low and high flow rates display a distinct core-shell 
architecture that has been extensively described in multiple in vitro and in vivo studies 
[92,93]. It is interesting that although the flow direction with respect to the clots is different, 
the pattern of a highly activated (P-selectin-positive) and fibrin rich core surrounded by a 
P-selectin-negative, less dense platelet shell was still maintained. Thrombin generation 
and fibrin at the collagen/TF surface colocalized with the majority of the platelet activation 
in the core of these clots. 
4.3.3 N-acetylcysteine reduces platelet deposition near stagnation points 
To analyze the role of VWF in thrombus formation in this geometry, CTI whole 
blood labeled with fluorescent anti-CD61 and anti-VWF was perfused over a collagen/TF 
surface at 10 and 100 µL/min (Figure 4-4). At both flow rates, VWF firmly adhered to the 
collagen surface, but was also found throughout the platelet structure. Some incorporation 
of VWF onto the collagen surface was expected, even at lower shear rates [94].  
Previously, it has been shown that NAC promotes disaggregation of arterial 
thrombi by interfering with the platelet/VWF interactions and interfering with disulfide 
bonds inside multimeric VWF [4,7]. To investigate if NAC had a similar effect during the 
formation of stagnation point thrombi, the assay was repeated with a high dose of NAC. 
When 30 mM NAC was added to the whole blood before perfusion, platelet adhesion was 
drastically reduced in the low flow rate condition, and was eliminated in  
66 
 
 
Figure 4-4: NAC reduced the height of stagnation point clots 
High CTI whole blood was perfused over collagen/TF surfaces at an inlet flow rate of 10 
μL/min or 100 μL/min with or without 30 mM NAC. Clots formed with NAC were smaller 
and contained less VWF than the control clots. 
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the high flow rate condition. Despite the much smaller thrombus in the low flow rate 
condition, the platelets still co-localize with VWF, but the amount of VWF overall was 
decreased from the control condition without NAC. 
4.3.4 Polymerized fibrin was not required for clot stability 
In clot formation under unidirectional flow, fibrin plays an important role in clot 
stability and in preventing embolization [58]. To examine the role of fibrin in the stagnation 
point geometry, the peptide Gly-Pro-Arg-Pro (GPRP) was used to inhibit the 
polymerization of fibrin monomers into fibrin polymer. Whole blood anticoagulated with 
CTI was incubated with and without 1 mM GPRP prior to perfusion at 10 and 100 μL/min 
over a collagen/TF surface (Figure 4-5). When fibrin polymerization was inhibited, the 
overall structure of the platelet mass and VWF accumulation appeared similar to that seen 
with fibrin present. 
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Figure 4-5: Polymerized fibrin was not required for stagnation point clot stability 
High CTI whole blood was perfused over collagen/TF surfaces at an inlet flow rate of 10 
μL/min or 100 μL/min with or without 1 mM GPRP, which inhibited fibrin polymerization. 
The absence of polymerized fibrin did not lead to clot instability. 
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4.4 Discussion 
The development of in vitro microfluidic assays have been useful in probing the 
mechanisms by which clots grow under flow [46,48]. In this study, we were able to examine 
the clot morphology resulting from pathologically relevant flows by designing a microfluidic 
device capable of generating stagnation point flows on a thrombotic collagen/TF surface. 
One advantage to this device is the creation of an essentially two-dimensional stagnation 
flow, which more closely recapitulates the flow and transport found around stagnation 
points in stenosed blood vessels compared to the radial flow stagnation points deployed 
in previous studies. This study was the first to observe that clots formed at/near stagnation 
point flows adopt a core-shell architecture, just like those observed previously in parallel 
flows both in microfluidic studies [46] and mouse studies [95]. 
Another advantage over previous stagnation studies is the side-view orientation of 
this microfluidic device, which enables direct observation of clot growth and the ability to 
see spatial differences along the growth axis in qualities such as P-selectin activation, 
fibrin generation, or VWF incorporation. This fact allows the in vitro thrombi grown in this 
device to be compared to in vivo intravital mouse imaging, future comparisons between 
the well-controlled flow and whole blood conditions in vitro to the more complex and 
physiological in vivo environment and geometry.  
The addition of NAC into the system had a pronounced effect on platelet deposition 
around the stagnation point. At low shear rates, NAC seemed to interfere with VWF-VWF 
interactions, as observed in previous work [4], reducing the overall platelet deposition. At 
high shear rates, however, NAC abolished platelet deposition on collagen/TF, suggesting 
a role for VWF in the high shear environment around stagnation points. VWF observed in 
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the platelet mass itself could be both plasma and/or platelet derived. The VWF closer to 
the top of the clot was likely to be plasma VWF due to the increased shear gradients on 
the surface of the clot as it grows, but also because the platelets in the top of the clot (the 
shell) were P-selectin-negative, suggesting the platelet VWF was probably not present in 
the shell. However, the large amount of VWF present at the base of the clots for both flow 
rates suggested that there may be a combination of plasma and platelet VWF in the core 
as both high shear gradients and platelet activation were present. In future work, an 
examination of the colocation of P-selectin exposure and VWF in the core and the shell 
could provide interesting insights about the origins of the clot-incorporated VWF. 
Further study into mechanisms of VWF involvement could be conducted with von 
Willebrand disease patient whole blood to see if the absence or dysfunction of VWF 
eliminates stagnation point clots. Although this model does not imitate the moving 
stagnation points found in some vessel geometries due to pulsatile flows with a 
recirculation eddy, this device has allowed for the study of thrombus formation in steady 
flow conditions. This device may be suited for studying clotting in pulsatile inlet flow 
conditions where the stagnation point doesn’t move. Additionally, a more detailed 
calculation of the cell-free layer and hematocrit could be achieved using a particle 
suspension model [96] to further improve the computational fluid dynamics model.  
The effect of GPRP on thrombus structure in this geometry was not initially 
expected, since fibrin is thought to be important in the stability of thrombi formed in parallel 
flow. The unique flow situation of stagnation point flow seem to play an important role in 
clot stability by providing perpendicular fluid forces keeping the thrombus more securely 
held to the collagen/TF surface. As the thrombus grows further away from the stagnation 
point, where the flow conditions become more like parallel flow, it is expected that the clot 
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stability would again become dependent on fibrin. Additional studies examining the effect 
of tissue plasminogen activator on thrombus stability may provide additional evidence in 
understanding the role of fibrin in stagnation point thrombi. 
In summary, we report a model for the study of thrombus formation around 
stagnation points to probe clot structure and help to elucidate the mechanisms involved. 
4.5 Summary 
In regions of flow separation/reattachment within diseased arteries, the local 
hemodynamics can result in stagnation point flow that provides an atypical environment 
in atherosclerosis. Impinging flows occur with recirculation eddies distal of coronary 
stenosis or diseased carotid bifurcations. By perfusing whole blood directly perpendicular 
to a fibrillar collagen thrombotic surface, a microfluidic device produced a stagnation point 
flow. Side view visualization of thrombosis in this assay allowed for observation of clot 
structure and composition at various flow rates and blood biochemistry conditions. For 
clotting over collagen/tissue factor surfaces, platelet thrombi formed in this device 
displayed a core-shell architecture with a fibrin-rich, platelet P-selectin-positive core and 
an outer platelet P-selectin-negative shell. VWF was detected in clots at low and high 
shear, but when N-acetylcysteine was added to the whole blood, both platelet and VWF 
deposition were markedly decreased at either low or high flow. To further examine the 
source of clot stability, 1 mM GPRP was added to prevent fibrin formation while allowing 
the PAR1/4-cleaving activity of thrombin to progress. The inhibition of fibrin polymerization 
did not change the overall structure of the clots, demonstrating the stability of these clots 
without fibrin. Impinging flow microfluidics generate thrombi with a core-shell structure. 
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CHAPTER 5: OTHER STUDIES 
5.1 Shear-Induced Platelet Activation 
5.1.1 Introduction 
Platelet activation under high shear conditions is a poorly understood process. 
Mechanistically, shear-induced platelet activation (SIPA) involves the shear-mediated 
binding of VWF to GPIb on the platelet membrane. The binding event provides outside-in 
signaling that increases intracellular calcium and activates GPIIb/IIIa, which allows the 
platelet to stably bind to VWF. The increase in intracellular calcium leads to overall platelet 
activation, including granule release and P-selectin exposure. It is thought that SIPA may 
play a role in the pathogenesis of diseases such as myocardial infarction [97] due to SIPA 
observed in in vitro experiments. Because most shear-induced platelet activation studies 
are conducted using a cone-plate viscometer [72,98], it isn’t possible to observe the 
activation of a single platelet over time. Additionally, since platelets in a thrombus 
experience shear from fluid flowing around them while they are held in place, these studies 
do not replicate the in vivo flow conditions that cause platelets to activate in a thrombus.  
5.1.2 Methods 
The impingement-micropost device and a 60 μm-wide stenosis device were used 
in conjunction to capture platelets on VWF from whole blood and to then observe platelet 
activation in real-time. To analyze the localization of strain on the VWF fiber as it is 
stretched by the increased flow rate, iterative particle image velocimetry (PIV) analysis 
was used (ImageJ plugin PIV). This technique cross-correlated the position of regions on 
the VWF fiber under increasing amounts of shear stress and used the integrated 
displacement of each region along the fiber as an approximation for local strain. The 
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stenosis microfluidic devices were placed over a patterned VWF strip adsorbed on the 
glass slide to mimic non-stretchable VWF. 
5.1.3 Results and Discussion 
To get a better idea of the local strain environment of VWF fibers under shear flow, 
particle image velocimetry (PIV) was conducted to analyze the relative displacements of 
points on the fluorescently labeled VWF fiber as it stretched under step increases in shear 
rate. Fluorescent images of VWF were processed using PIV, and the average cumulative 
displacement of the VWF regions was found for both in the post region and the fiber region 
(downstream of the post). VWF fibers within the fiber region experienced significantly more 
stretching than the VWF in the post region, probably due to the friction between the VWF 
and post (Figure 5-1). Because it has previously been observed that most of the activated 
platelets on VWF are located in the fiber region [19], and the local wall shear rate on the 
fiber is highest around the post, the increased strain could play a small role in activation 
through mechanical stressing and outside-in signaling. 
To examine this potential role, a comparison of platelet activation on a stretchable 
VWF surface to a rigid VWF surface was examined. When PPACK/apixaban whole blood 
(with labeled platelets and P-selectin) was perfused over VWF fibers formed from 
PPACK/apixaban/citrated PFP at 1000 s-1 for 2 minutes, stable platelet adhesion along 
the length of the VWF fiber was observed. The fluid was then switched to a buffer 
containing anti-CD62P to visualize P-selectin activity. From this starting position, a 
stepwise increase in shear rate (1000 s-1 every minute up to 12,000 s-1) resulted in 
increasing platelet activation as measured by P-selectin fluorescent area per platelet area 
(Figure 5-2A). When this whole blood perfusion and subsequent platelet exposure to shear 
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was repeated over a strip of adsorbed recombinant VWF, platelets also firmly adhered 
and activated in response to an increase in shear (Figure 5-2B). Because the P-selectin 
per platelet area for both forms of VWF is similar at all tested shear rates, it is unlikely that 
the stretching of fibrous VWF is significantly contributing to the activation of platelets via 
pulling on αIIbβ3 on the platelets (Figure 5-2C). Because strongly activated platelets are 
less likely to fall off of VWF due to high shear, it is observed that the proportion of activated 
platelets increases over time on both forms of VWF (Figure 5-2D).   
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Figure 5-1: Strain concentrates in the fiber region of VWF 
VWF fibers labeled with a fluorescent antibody were stretched in a stepwise fashion from 
1000 s-1 to 12,000 s-1 in 1000 s-1 steps every 60 seconds. The VWF fluorescent image 
was analyzed using PIV plugin for ImageJ to cross-correlate the displacement of regions 
on the VWF fiber. Cumulative strain (represented in heat map form) was approximated by 
total displacement of the regions. VWF in the fiber region accumulated more strain than 
the VWF in the post region. 
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Figure 5-2: Platelets increasingly activate at higher shear rates on both fibrous and 
patterned VWF 
(A) Citrated PFP inhibited by PPACK and apixaban was perfused through the 
impingement-micropost device at 10,000 s-1 to form VWF fibers. The shear rate was then 
reduced to 1000 s-1 and the fibrous VWF was labeled using polyclonal fluorescent anti-
VWF antibody in HBS. After washing out with HBS to reduce background, PPACK- and 
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apixaban-inhibited whole blood labeled with fluorescent anti-CD41 (platelets) and anti-
CD62P (P-selectin) was perfused over the VWF fibers for 2 min. After washing out the 
whole blood in the channel with HBS, fluorescently labeled anti-CD62P labeled HBS was 
perfused for 1 min at each 1000 s-1 step in shear rate, from 1000 s-1 to 12,000 s-1. (B) 
Recombinant VWF was patterned on a glass slide using a microfluidic patterning device 
previously described.[48] A 60 μm wide stenosis channel was placed over this VWF strip 
perpendicularly to create a 60 μm x 100 μm patch of adsorbed VWF in the channel. The 
same procedure from A was used for perfusion of whole blood and subsequent platelet 
exposure to shear. (C) Platelets on both fibrous and patterned VWF increasingly activated 
with increasing shear rate. There was no significant difference in platelet activation 
between the stretching fibrous VWF and the non-stretching patterned VWF. (D) Both 
forms of VWF experienced similar platelet loss as shear increased, contributing to the P-
selectin/platelet increase with shear.  
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5.2 Effect of N-Acetylcysteine on VWF aggregation 
5.2.1 Introduction 
VWF aggregation into fibers occurs in regions of high shear rate, such as in the 
irregular flows of a vessel injury or on the top of a nearly-occlusive thrombus. This self-
association of VWF from plasma is necessary for significant platelet recruitment in these 
high shear areas. Because nearly-occlusive thrombi can lead to a number of conditions, 
such as stroke, it is important to understand potential mechanisms for inhibiting VWF’s 
role in the process. 
N-acetylcysteine (NAC) is an FDA-approved antioxidant drug that is used for 
treating acetaminophen overdose and for loosening thick mucus in patients with cystic 
fibrosis or chronic obstructive pulmonary disease. In recent studies, it is thought to reduce 
the size of soluble plasma VWF multimers and degrade ULVWF multimer strings released 
from endothelial cells [99]. Stenosis-shaped microfluidic devices can be used to better 
understand the potential use of NAC in treating thrombosis. 
5.2.2 Methods 
In this study, a protocol was developed to quantify the formation of VWF fibers on 
a collagen surface at pathological shear rates. To do this, a 100 μm wide collagen strip 
was applied to a glass slide using a microfluidic patterning device as previously described 
[48]. A stenosis-shaped channel with a width of 15 μm was then placed perpendicularly 
on top of the collagen, so that collagen was only exposed in the constant-width region of 
the stenosis. Citrated PFP was then perfused through the device at 30,000 s-1 for 5 min, 
resulting in VWF fiber deposition on the collagen. After washing out the plasma with 0.5% 
BSA, labeling the VWF with fluorescent anti-VWF antibody, and then reducing the 
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background with HBS, the now-fluorescent VWF fibers formed on the surface were able 
to be visualized. Once fluorescent images were captured of the VWF fibers, ImageJ was 
used to measure the length of and count each VWF fiber deposited in each channel, and 
a histogram of all measured fiber sizes for each condition was created.  
5.2.3 Results and Discussion 
As a test of this protocol, a comparison of citrated PFP with or without NAC was 
conducted. When 30 mM NAC was perfused over already formed VWF fibers, they did not 
dissolve back into solution [19]. However, it has not previously been demonstrated 
whether NAC might interfere with the action of plasma VWF aggregation. When 30 mM 
NAC was added to citrated PFP and perfused over collagen at 30,000 s-1 for 5 min, fewer 
and smaller VWF fibers formed on the collagen than in the HBS-treated control (Figure 
5-3A), significantly for fibers 10-20 μm and 20-50 μm in length (Figure 5-3C). When 
examining the histogram of fiber sizes, the addition of NAC resulted in a downward shift 
in the size distribution of VWF fibers (Figure 5-3B). It was also observed that in the 
presence of NAC, the total length of all fibers formed was less than half that of the control. 
These results would suggest that NAC may play a role in inhibiting VWF aggregation into 
fibers on the surface of collagen, opening the door for a potential application in inhibiting 
high shear thrombosis. 
A study by de Lizarrondo et al. [4] provides additional evidence suggesting the 
NAC may be a safe alternative to antithrombotic agents in restoring vessel patency after 
arterial occlusion. They demonstrate through a combination of in vivo and in vitro 
experiments that intravenous NAC administration promotes the lysis of arterial thrombi 
that are resistant to recombinant tPA, direct thrombin inhibitors, and antiplatelet 
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treatments. They also provide evidence that NAC primarily targets the VWF that crosslinks 
platelets in arterial thrombi, leading to disaggregation.   
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Figure 5-3: N-acetylcysteine reduces VWF aggregation on collagen 
(A) Citrated PFP with either 30 mM N-acetylcysteine (NAC) or HBS (control) was perfused 
over a 100 μm wide collagen strip at 30,000 s 1 for 5 min. The channel was then washed 
with 0.5% BSA, labeled with a polyclonal fluorescent anti-VWF antibody in HBS, and then 
HBS to reduce background before imaging. (B) The length of each VWF fiber in each 
image was measured, resulting in a size distribution of VWF fibers for both the control and 
NAC conditions. (C) Inclusion of NAC in citrated plasma resulted in a lower number of 
VWF fibers formed, and a significantly reduced number of 10-20 μm and 20-50 μm fibers 
compared to the control [4].  
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5.3 Role of GPVI in Trauma 
5.3.1 Introduction 
During trauma, major changes in blood biochemistry occur as a result of 
hemorrhagic shock, endothelial release of tPA, release of tissue factor (TF) into the 
vasculature, and systemic inflammatory events [100,101]. Since both thrombin and 
plasmin are generated in the systemic circulation following trauma, elevated levels of 
thrombin-antithrombin complexes and fibrin degradation products have been observed 
[102–105]. Platelets obtained from trauma patients can display a hypofunctional 
phenotype, despite baseline platelet counts and platelet P-selectin levels that are 
comparable to healthy individuals [105].  
Platelet GPVI is an immunoglobulin superfamily receptor present at about 4000 
copies/platelet [106], corresponding to about 1 nM concentration in platelet rich plasma 
(PRP). Although GPVI is thought to primarily bind to collagen during clot formation, recent 
evidence has shown insoluble fibrin’s ability to both bind and agonise GPVI on platelets 
within a forming clot [107,108]. However, the function of soluble fibrin species on platelets 
in circulation (as in trauma) is not well understood. We hypothesized that platelet 
hypofunction can result from low levels of soluble fibrin in circulation, and utilized the 8-
channel microfluidic device with exogenous soluble fibrin to test for any change in platelet 
function on collagen [109]. 
5.3.2 Methods 
Fluorescent fibrinogen (0.788 mg/mL) was incubated in either 5 mM GPRP or HBS 
(control condition) for 10 min. Following incubation, 2.5 nM thrombin was added to each 
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aliquot to generate either soluble fibrin monomer (GPRP present) or soluble fibrin polymer 
(HBS control). After 300 seconds, thrombin activity was inhibited with 100 µM PPACK. 
The resulting solutions were diluted by a factor of 10 in PPACK/apixaban-treated whole 
blood (treated to prevent endogenous thrombin production or thrombin activity). Under the 
conditions of this experiment, platelets in whole blood were not exposed to active 
thrombin. In the 8-channel microfluidic device, platelet deposition from whole blood with 
230 nM soluble fibrin monomer (GPRP condition) or 230 nM soluble fibrin polymer (HBS 
control condition) was then tested for platelet deposition on collagen at a wall shear rate 
of 200 s-1 (Figure 5-4A).  The deposited platelet and fibrin fluorescence intensities were 
recorded every minute for 6 minutes. 
5.3.3 Results and Discussion 
As expected, 5 mM GPRP substantially blocked the amount of fibrin that co-
deposited with the platelets (Figure 5-4C-E). This indicated that fibrin monomer at 230 nM 
was outcompeted for platelet binding by ~8000 nM fibrinogen in the whole blood. In 
contrast, 230 nM soluble fibrin polymer added to whole blood was able to co-deposit with 
platelets, even in the presence of normal levels of fibrinogen. Consistent with a defect in 
collagen-induced platelet activation via GPVI, the presence of soluble fibrin polymer (HBS 
control condition) caused a substantial reduction of platelet deposition on collagen (Figure 
5-4B-E), especially after ~100 seconds when ADP and thromboxane release are 
especially important for platelet buildup [110]. GPVI is not required for firm adhesion to 
collagen but does lead to strong calcium mobilization to drive granule release, α2β1 
activation, COX-1 activation, and αIIbβ3 activation required to support secondary 
aggregation. 
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Additional evidence from pairwise agonist scanning [109] found that exposure of 
apixaban-treated platelet-rich plasma (12% PRP) to thrombin (1-10 nM) for 500 seconds, 
but not ADP or thromboxane mimetic U46619 exposure, dramatically blocked subsequent 
GPVI activation by convulxin or collagen-related peptide. The onset of convulxin-
insensitivity required 200 to 500 seconds of thrombin exposure, was not mimicked by 
exposure to PAR-1/4 activating peptides, was not observed with washed platelets, and 
was blocked by fibrin polymerization inhibitor (GPRP) or Factor XIIIa inhibitor (T101), 
which is consistent with soluble fibrin binding GPVI. Since only 1% conversion of plasma 
fibrinogen generates 90 nM soluble fibrin (which exceeds ~1 nM GPVI in blood), circulating 
platelets in coagulopathic blood may display an acquired GPVI-deficiency that impacts 
hemostasis, even for transfused platelets. 
Distinct from the role of intrathrombus generation of fibrin, low levels of non-gelling, 
soluble fibrin may function differently in the context of trauma to cause an acquired GPVI-
deficiency in the systemic circulation. Under flow conditions, platelets exposed to soluble 
fibrin species displayed less accumulation on a surface of fibrillar collagen. Generation of 
low and transient levels of thrombin in coagulopathic blood may generate circulating 
soluble fibrin able to bind platelet GPVI to cause platelet insensitivity to stronger GPVI 
agonists such as collagen of the damaged vessel wall. Understanding mechanisms behind 
platelet hypofunctionality may be relevant to transfusion therapies, and other clinical 
interventions.  
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Figure 5-4: Under thrombin-free conditions, presence of soluble fibrin in whole 
blood reduces platelet adhesion on collagen under flow  
(A) Schematic of experimental protocol. Fluorescent fibrinogen was exposed to 2.5 nM 
thrombin with either 5 mM GPRP (inhibit fibrin formation) or HBS (control). After 300 s, the 
thrombin was quenched with 100 μM PPACK. This reacted fibrinogen/fibrin solution was 
diluted by a factor of 10 into PPACK/apixaban-inhibited whole blood with either 5 mM 
GPRP or HBS and then perfused through an 8-channel microfluidic device at 200 s-1 over 
a collagen surface. (B) GPRP increased platelet deposition on the collagen surface after 
60 s. (C) Fibrin co-deposition with platelets was significantly decreased with 5 mM GPRP. 
(D) At 120 s, soluble fibrin monomer (GPRP present) resulted in more platelet deposition 
to collagen, while soluble fibrin polymer (no GPRP) resulted in less platelet adhesion to 
collagen. (E) At 240 s, platelet deposition and aggregation on collagen was quite 
pronounced in the presence of GPRP which blocked fibrin co-deposition, as expected 
[109]. 
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CHAPTER 6:  FUTURE WORK 
6.1 Shear-Induced Platelet Activation 
The impingement-post and stenosis microfluidic devices described in Chapters 3 
and 6 can be used to better understand the process of shear-induced platelet activation, 
including the triggers of activation, the process of activation, and how it affects single 
platelet behavior.  
It is currently unclear how the shear force on the platelet mechanistically translates 
to outside-in signaling and activation. Blebbistatin, a myosin II inhibitor, could be used to 
see if platelet retraction against the VWF substrate is responsible for SIPA. If the pulling 
force of platelets against VWF is necessary for activation, we would expect decreased 
activation in blebbistatin treated platelets. 
To understand when the effect of SIPA begins, it is important to find the critical 
shear rate to get calcium mobilization, phosphatidylserine exposure, and/or P-selectin 
exposure on adherent platelets when bound to fibrous and adsorbed VWF. By measuring 
the fluorescence of multiple markers of activation, such as calcium dye, Annexin V, and 
P-selectin antibody, while increasing the shear rate in a stepwise fashion, it is possible to 
determine the multiple stages of platelet activation and their implications in thrombus 
growth. One complication to this study would be that it is unclear whether the amount of 
time at a given shear rate has a significant effect on platelet activation. For instance, if a 
platelet experiences a lower shear rate of 1000 s-1, will it take longer to activate, reach a 
certain level of activation and stop, or will it not activate at all? If the shear rate is increased 
to 5000 s-1 after experiencing 1000 s-1 for some number of minutes, are the platelets more 
likely to stay adherent to the VWF due to a higher activation level, or will they simply reach 
a higher level of activation? Though these sudden shifts in shear rate are unlikely to occur 
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in vivo, this kind of experimentation will help us better understand the on-off process of 
platelet binding to VWF fibers, enabling better models of thrombus formation. To account 
for this difficulty, a series of experiments comparing the 3 activation measures at different 
shear rates, different shear increase steps, and different times at each shear, a more 
complete image of the effect of shear rate over time on platelet activation can be 
assembled. 
It is known that more highly activated platelets are more strongly adherent, but the 
exact nature of this relationship is still unknown. Using fluorescent video capture, single 
platelets bound to VWF fibers or patterned VWF can be tracked for their response to shear 
exposure over time. By correlating extent of activation with the likelihood that a platelet 
will fall off of the VWF, it is possible to quantify the adhesion strength of activated platelets 
on VWF fibers, which could inform how steady state VWF-platelet aggregates form in 
thrombosis. The information from this study would be directly applicable in simulations of 
thrombus formation. 
Since VWF adhesion to collagen during the beginning stages of clotting also 
occurs at high shear, it is important to determine the effect of SIPA on collagen/VWF 
surfaces. Some preliminary work has been done in patterning 100 μm wide strips of 
collagen, VWF, or collagen/VWF on a glass slide, and using a 60 μm wide stenosis device 
to perfuse PPACK/apixaban WB at 1000 s-1 or 5000 s-1 for 7 minutes (Figure 6-1A). By 
measuring platelet adhesion and P-selectin exposure as a marker of activation, the 
importance of substrate in SIPA can be measured. Since platelets had to firmly adhere 
first in order to display P-selectin, the platelet adhesion behavior on these surfaces was 
quantified (Figure 6-1B). At 1000 s-1, patterned VWF alone was not sufficient for platelet 
adhesion, but both collagen and collagen/VWF supported significant platelet adhesion, 
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with the collagen/VWF condition leading to more platelet accumulation at longer times. 
When WB was instead perfused at 5000 s-1, platelet adhesion on the collagen surface was 
severely reduced to the level of patterned VWF. However, collagen/VWF was able to 
support stable platelet adhesion. This result is not a surprise, since it is well known that 
VWF is needed for platelet adhesion at higher shear rates, but the accompanying platelet 
activation does begin to tell an interesting story.  
When the platelet activation pattern is examined, it is evident that platelets bound 
to collagen/VWF surfaces are not significantly different than platelet bound to collagen 
surfaces at 1000 s-1 (Figure 6-1C). However, when the prevailing shear rate is 5000 s-1, a 
higher ratio of platelets are activated to the point of P-selectin exposure, and are activated 
throughout thrombus formation. Though this seems to be partially driven by the lower 
numbers of adherent platelets at 5000 s-1, those that do stick are likely more activated and 
have more bonds with the VWF on the surface to withstand the high shear forces in the 
free blood flow. In contrast, there was no P-selectin exposure in the collagen condition at 
5000 s-1. The platelets aren’t able to form high shear bonds with GPIb on collagen, 
resulting in less platelet deposition at high shear. Additional experiments are necessary to 
determine how much of an effect the addition of VWF to collagen has on platelet activation.  
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Figure 6-1: Shear-induced platelet activation on collagen/VWF surfaces 
(A) PPACK/apixaban WB was perfused over a collagen or collagen/VWF surface at 1000 
s-1 or 5000 s-1 for 7 minutes. (B) At 1000 s-1, there was increased adhesion of platelets on 
the collagen/VWF surface than either collagen or patterned VWF surfaces alone. At 5000 
s-1, collagen/VWF was the only surface that was able to accumulate platelets away from 
the slower flow on the edges of the channel, since VWF is required for platelet adhesion 
at high shear. (C) Using P-selectin as a marker for platelet activation, it was observed that 
shear-induced platelet activation dominates at 5000 s-1. No significant activation was 
observed in the collagen condition at 5000 s-1 due to an overall lack of platelet adhesion. 
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There are a couple factors that may be having an effect. First, since the VWF 
patterned on top of the collagen is done so in an adsorptive manner, it is not clear if the 
VWF availability to platelets in flow is the same as VWF deposited on collagen surfaces 
at high shear rates. To test this, VWF fibers can be deposited at high shear rates on a 
patterned collagen surface. After VWF fibers are detected on the surface, whole blood can 
be perfused at high shear rates to measure adhesion and activation on this more 
physiologically relevant substrate as a function of VWF deposited. There also may be an 
alignment effect of VWF, where VWF fibers aligned with flow (similar to in vivo) may be 
able to better bind and capture platelets due to closer downstream proximity to 
platelet/VWF binding sites. Second, because WB is perfused at high shear rates in this 
experiment, there may be some VWF deposition on either collagen or on top of platelets, 
as previously seen in Colace et al. [38]. To measure this, VWF in WB can be labeled with 
a fluorescent antibody, so any additional VWF deposition above the initial baseline can be 
quantified as the thrombus grows. Since these clots are formed at a constant flow rate, 
we would expect VWF deposition to occur at the beginning of the experiment on the 
exposed collagen surface, and again later in the experiment at the top of the thrombi, 
since shear rates here will be elevated as the thrombus occludes the channel.  
Since thrombin was inhibited in the preliminary results to remove thrombin-based 
platelet activation, it is not clear how significant of a role thrombin plays at high shear 
rates. One hypothesis would be that thrombin washes out too quickly at high shear rates 
to have as significant of an effect, but platelets close to the point of thrombin generation 
(primarily in the core) may still be affected. If this is the case, then the in vivo mechanism 
for SIPA would be more important at the top of the clots, where thrombin has limited 
access due to flow conditions. A set of experiments where thrombin is not inhibited would 
91 
 
help to determine if the activation of platelets in high shear thrombus formation is 
significantly different with thrombin, further elucidating its role at high shear. 
6.2 Effect of N-Acetylcysteine on VWF aggregation 
Since NAC was unable to dissolve thick VWF fibers formed in the impingement-
post microfluidic device [19], it is unclear if NAC is only effective when VWF fibers are 
thinner, such as when crosslinking platelets. Though de Lizarrondo and colleagues [4] 
provided some in vivo evidence that NAC targets the VWF crosslinking arterial thrombi, it 
is not clear whether NAC actually cleaves VWF multimers within the clot, or if it merely 
interferes with the VWF/platelet interactions in the formation of the top of the clot. A few 
experiments may be able to provide greater clarity into these two potential hypotheses. 
To distinguish between these mechanisms, the formation of VWF-rich clots on the 
post of the impingement-post microfluidic device can be used. By perfusing citrated whole 
blood (WB) through the device at 10,000 s-1 with and without NAC, it will be possible to 
compare the size of the platelet/VWF accumulation to determine if NAC is interfering with 
the platelet/VWF interactions in the formation of the clot. Since NAC has been shown to 
reduce the multimer sizes of circulating VWF, we would expect NAC would result in 
smaller clots at steady state. Although this experiment alone cannot determine the 
mechanism, it can be used in conjunction with the following experiments to triangulate the 
role of NAC in this system. 
To test the VWF cleavage hypothesis, a platelet/VWF clot can be formed using 
citrated WB, followed by citrated WB with NAC. If the thrombus size decreases over time, 
NAC is likely cleaving VWF crosslinks between the platelets, since no collagen or fibrin is 
present in this experiment. To confirm this result, a clot formed on a collagen surface at 
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high shear can be challenged with NAC to see if the VWF shell of the clot dissolves in the 
presence of NAC, while the primarily platelet/collagen interactions of the core remain 
stable. 
These experiments would provide valuable insight into the potential uses of NAC 
as an antithrombotic therapy in diseases like coronary artery disease or stroke. If NAC 
primarily interferes with platelet/VWF interactions during clot formation, it could be used 
as a preventative measure to prevent smaller thrombi from propagating to fully occlusive 
clots as they are exposed to higher shear rates. Initial results from de Lizarrondo and 
colleagues suggest that NAC does not work as a preventative treatment in the ferric 
chloride injury model [4], but since the formation of ferric chloric thrombi is rapid and driven 
by oxidative stress [111], there may be a kinetic argument for the potential efficacy of NAC 
in stroke prevention. This hypothesis could be tested by measuring growth rates of thrombi 
in microfluidico either from initial platelet adhesion or as a treatment in blood for growing 
thrombus that is growing to reach occlusion.  
However, if NAC does act as a thrombolytic agent by cleaving VWF/VWF bonds 
or VWF/platelet bonds, then it has potential to be used in more occlusive vessels to reduce 
the size of nearly occlusive clots, as demonstrated in the ferric chloride mouse model [4]. 
It is, of course, possible for both mechanisms to be important, which would only improve 
NAC’s potential as a treatment for ischemic stroke. 
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CHAPTER 7: CONCLUSION 
Microfluidic techniques enable the study of thrombosis in flow environments that 
mimic the pathological environment of many thrombotic diseases. Using these techniques, 
we find that the aggregation of VWF multimers into fibers paired with bound platelet 
activation under shear to be significant contributors to the formation of thrombi under high 
shear conditions.  
In Chapter 1, we review important mechanisms of thrombus formation, including 
the roles of platelets, coagulation, VWF, and hemodynamics. These concepts serve as a 
background for the other sections to give an idea of the many mechanisms involved 
simultaneously in clot formation. In Chapter 2, a guide for designing new microfluidic 
devices was compiled, including descriptions of common features and important design 
considerations for making a new device. Using this chapter as a guide, new devices can 
be developed in the future to better understand the mechanisms involved in thrombosis. 
In Chapter 3, the impingement-post device was developed to study fibrous VWF 
and its role in coagulation and platelet thrombus formation. This device was the first to 
isolate aggregated VWF fibers without the use of collagen. It was found that fibrous VWF 
is non-amyloid, resistant to ADAMTS13 and tPA, and captures FXIIa during aggregation 
allowing coagulation to proceed on its surface. Platelets also bind and activate on the 
surface of VWF fibers in a shear-dependent manner. In Chapter 4, the stagnation point 
device was developed to study the formation of thrombi at stagnation points relevant to 
reattaching flows. These clots were found to have a core-shell structure, were VWF-rich, 
and were sensitive to the addition of NAC, suggesting that platelet/VWF interactions were 
crucial for clot stability. However, fibrin polymerization was not required for stable 
thrombus formation in this flow geometry.  
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In Chapter 5, a series of side projects were discussed, including the shear-induced 
platelet activation on VWF, the effect of NAC on thrombus formation, and the effect of 
soluble fibrin on GPVI activation by collagen and its role in trauma. When studying shear-
induced platelet activation, it was observed that platelet activation was not primarily driven 
by the strain of the stretching VWF substrate, because platelets bound to both fibrous and 
sorbed VWF displaced similar levels of activation. In studying the effect of NAC on 
thrombus formation, it was found that NAC reduces VWF deposition on collagen, with a 
smaller average fiber length and smaller volume of VWF fiber deposition on the collagen 
surface. In studying GPVI in trauma-like conditions, soluble fibrin led to decreased platelet 
deposition on collagen, which in conjunction with calcium assays, suggest soluble fibrin 
can reduce GPVI binding by collagen. In Chapter 6, some future experiments were 
suggested to gain greater clarity about the mechanisms involved in shear-induced platelet 
activation on VWF and about NAC’s potential antithrombotic use.  
Together, the findings presented here are related to many of the processes that 
occur during thrombosis, including the interactions between high shear blood flow, VWF, 
and platelet activation. As demonstrated in the above studies, microfluidics provide a 
valuable tool for studying high shear thrombosis in a controlled setting to discover potential 
mechanisms that help us predict in vivo behavior. The devices discussed in this thesis will 
be valuable tools for understanding how potential therapeutics, such as NAC, affect 
thrombus formation and stability. 
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